

Curriculum Vitae

Full Name: Se-Hoon Lee

Position Title: Professor

Address: Division of Hematology/Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
81 Irwon-Ro, Gangnam-gu,
Seoul, 06351, South Korea

Telephone number: 82-2-3410-1132, 0295

Fax number: 82-2-3410-1757

Email address shlee119@skku.edu
sehoon.lee119@gmail.com

Education:

Institution and Location	Degree	Year Conferred	Field of Study
College of Medicine, Seoul National University Seoul, Korea	M.D.	1996	Medicine
Graduate School, Seoul National University, Seoul, Korea	M.S.	2001	Medicine
Graduate School, Seoul National University, Seoul, Korea	Ph.D.	2008	Medicine
Seoul National University Hospital, Seoul, Korea	Internship & Residency	2001	Dept. of Internal Medicine
Seoul National University Hospital, Seoul, Korea	Fellowship	2002	Section of Hematology/Medical Oncology, Dept. of Internal Medicine
Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Fellowship	2004	Division of Hematology & Medical Oncology, Dept. of Medicine

Research and Professional Experience:

Position	Institution/Employer and Location	Dates of Employment
Professor	Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	Mar, 2015~
Visiting Scholar	Dana-Farber Cancer Institute, Boston, MA (Harvard Medical School) Broad Institute, Cambridge, MA	Jul, 2009~Jan, 2011
Assistant & Associate Professor	Seoul National University Hospital, Seoul National University College of Medicine	Apr, 2005~Feb, 2015
Clinical Instructor	Samsung Medical Center, Seoul, Korea	Apr, 2004~Mar, 2005
Research Fellow	Samsung Medical Center	Mar, 2004~Apr, 2004
Clinical Fellow	Samsung Medical Center	Mar, 2002~Feb, 2004
Clinical Fellow	Seoul National University Hospital	May, 2001~Feb, 2002

2024~ Director of Clinical research institute, Samsung Medical Center

2022~2024 Director, Metagenome Center, Samsung Medical Center

Professional Memberships:

2022~ Director, Scientific Committee, Korean Society of Medical Oncology (KSMO)
2020~2022 Director, Multi-Disciplinary Committee, KSMO
2019~ Editorial board of Translational Lung Cancer Research
2017~ Editorial board of Experimental and Molecular Medicine

The Korean Association of Internal Medicine	2001
Korean Cancer Association (KCA)	2001
American Society of Clinical Oncology (ASCO)	2003
Korean Cancer Study Group (KCSG)	2003
Korean Society of Medical Oncology (KSMO)	2006
International Association for the Study of Lung Cancer (IASLC)	2007
American Association for Cancer Research (AACR)	2007
Korean Urological Oncology Society	2008
Korean Society of Neuro-Oncology (KSNO)	2011
Society of Neuro-Oncology (SNO)	2011
Korean Genome Organization (KOGO)	2012
Korean Society for Biochemistry and Molecular Biology (KSBMB)	2012
Korean Association for Lung Cancer (KALC)	2012
European Society for Medical Oncology (ESMO)	2015

**Relevant Clinical Trial Experience:
(selected, 2015~Aug. 2023)**

Phase II umbrella study of Immuno-oncology combo in NSCLC as a principal investigator in 2023
Phase II study of TKI in NSCLC as a principal investigator in 2023
Phase II study of ADC in NSCLC as a principal investigator in 2023
Phase II study of Bispecific Ab in NSCLC & HNSCC as a principal investigator in 2023
Phase I study of ADC in NSCLC as a principal investigator in 2022
Phase II study of Immuno-chemotherapy combo in HNSCC as a principal investigator in 2022
Phase II umbrella study of Immuno-chemotherapy combo in SCLC as a principal investigator in 2022
Phase II study of Immuno-chemotherapy combo I in HNSCC as an investigator in 2022
Phase II umbrella study of Immuno-oncology combo in NSCLC as a principal investigator in 2021
Phase II umbrella study of Immuno-oncology combo in NSCLC as a principal investigator in 2021
Phase II study of Monoclonal antibody in NSCLC as a principal investigator in 2021
Phase III of TKI in NSCLC as a principal investigator in 2021
Phase I study of Dual blocking antibody in NSCLC as a principal investigator in 2021
Phase II study of Antibody drug conjugate in NSCLC as a principal investigator in 2021
Phase II study of Immuno-oncology combo in NSCLC as a principal investigator in 2020
Phase I study of Monoclonal antibody in NSCLC as a principal investigator in 2020
Phase II study of Antibody drug conjugate in NSCLC as a principal investigator in 2020
Phase I study of Protein kinase inhibitor in solid tumor as a principal investigator in 2020
Phase I/II study of Immuno-oncology in NSCLC as an investigator in 2019
Phase III study of Immuno-oncology in NSCLC as a principal investigator in 2019
Phase I study of Small molecule as a principal investigator in 2019
Phase III study of Neoadjuvant Immuno-oncology combo in NSCLC as a principal investigator in 2018
Phase II study of Immuno-oncology in NSCLC as a principal investigator in 2018 (IST)
Phase II study of TKI in NSCLC as an investigator in 2018
Phase III study of Immuno-oncology in NSCLC as an investigator in 2018
Phase II study of Immuno-oncology in NSCLC as a principal investigator in 2017 (IST)

Phase II study of TKI in NSCLC as a principal investigator in 2017 (IST)
Phase I study of Immuno-oncology in NSCLC as an investigator in 2017
Phase I study of Immuno-oncology in NSCLC as a principal investigator in 2016
Phase II study of Immuno-oncology in NSCLC as an investigator in 2016
Phase III study of Immuno-oncology in NSCLC as an investigator in 2016
Phase II study of Monoclonal antibody in Mesothelioma as a principal investigator in 2016
Phase II study of Immuno-oncology in Thymic cancer as an investigator in 2016
Phase III study of TKI in NSCLC first-line as a principal investigator in 2016
Phase II study of CDK4/6 inhibitor in HNSCC as a principal investigator in 2015
Phase II study of Immuno-oncology in NSCLC as an investigator in 2015
Phase III study of TKI in NSCLC first-line as an investigator in 2015
Phase III study of Immuno-oncology in NSCLC as an investigator in 2015

I have participated in the clinical trials described above and additional ones not described.
GCP training was done at the investigator meeting more than 100 times till now.

I hereby certify that this document is an accurate representation of my qualifications.

Se-Hoon Lee, M.D.

Bibliography:

1. Alexander M, Cheng Y, [Lee SH](#), Passaro A, Spira AI, Cho BC, Lim SM, Ohe Y, Nagrial A, Tan JL, Wainsztein V, Ramos E, Campelo MDRG, Akamatsu H, Nguyen D, Cortot AB, Zer A, Erdem D, Sanborn RE, Emde TO, Minchom AR, Zurawski B, Ferreira ML, Yang JC, Marmarelis ME, Schuchard J, Alves J, Ghosh D, Balaburski G, Verheijen RB, Ribeiro L, Gamil M, Bauml JM, Baig M, Leighl NB. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. **Eur J Cancer**. 2025 Jul 10;227:115624. doi: 10.1016/j.ejca.2025.115624. Epub ahead of print. PMID: 40730077.
2. Jung HA, Lee D, Park B, Lee K, Lee HY, Kim TJ, Jeon YJ, Lee J, Park SY, Cho JH, Choi YS, Park S, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ, Kim HK. Deep-Learning Model for Real-Time Prediction of Recurrence in Early-Stage Non-Small Cell Lung Cancer: A Multimodal Approach (RADAR CARE Study). **JCO Precis Oncol**. 2025 Jul;9:e2500172. doi: 10.1200/PO-25-00172. Epub 2025 Jul 23. PMID: 40700672; PMCID: PMC12309513.
3. Park GH, Park S, Kim H, Jung HA, Sun JM, Ahn JS, Ahn MJ, [Lee SH](#). Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab. **Eur J Cancer**. 2025 Aug 26;226:115631. doi: 10.1016/j.ejca.2025.115631. Epub 2025 Jul 10. PMID: 40651388. [corresponding author]
4. [Lee SH](#), Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Dias JM, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Chih-Hsin Yang J, Besse B, Thomas M, Shah S, Baig M, Curtin JC, Zhang J, Xie J, Sun T, Sethi S, Wang M, Fennema E, Daksh M, Ennis M, Bauml JM, Cho BC. Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA. **J Thorac Oncol**. 2025 Jul 3:S1556-0864(25)00821-4. doi: 10.1016/j.jtho.2025.06.030. Epub ahead of print. PMID: 40617394. [first & corresponding author]
5. Jeong DY, Joe CY, Lee SM, Park S, Moon SH, Choi JY, Kim J, [Lee SH](#), Lee HY. Unraveling the tumor-microenvironment through a radiogenomic-based multiomic approach to predict outcomes of immunotherapy in non-small cell lung cancer. **Comput Methods Programs Biomed**. 2025 Sep;269:108915. doi: 10.1016/j.cmpb.2025.108915. Epub 2025 Jun 14. PMID: 40609133.
6. Kim H, Choi JH, Lim Y, Yoon SJ, Jang KT, Ock CY, Choi YH, Joe C, Song S, Moon J, Song H, Pereira S, Lee S, Park S, Kim K, [Lee SH](#), Kim H, Shin SH, Heo JS, Lee KH, Lee KT,

Lee JK, Han IW, Park JK. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. **JAMA Surg.** 2025 Jun 25:e251999. doi: 10.1001/jamasurg.2025.1999. Epub ahead of print. PMID: 40560550; PMCID: PMC12199178.

7. Kim J, Bang YH, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Jeon YJ, Lee J, Cho JH, Kim HK, Choi YS, Zo JI, Shim YM, Kang JH, Lee J, Choi YL, Han J, Hwang S, Lee HY, Lee SH. Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial. **EClinicalMedicine.** 2025 Jun 4;84:103282. doi: 10.1016/j.eclinm.2025.103282. PMID: 40524802; PMCID: PMC12169793. [corresponding author]

8. Sim H, Park GH, Park WY, Lee SH, Choi M. Single-cell-eQTL mapping in circulating immune cells reveals genetic regulation of response-associated networks in lung cancer immunotherapy. **Cancer Commun (Lond).** 2025 Jun 14. doi: 10.1002/cac2.70042. Epub ahead of print. PMID: 40515544. [corresponding author]

9. Piotrowska Z, Passaro A, Nguyen D, Ruiter G, Soo RA, Ho-Fun Lee V, Velcheti V, Tan DS, Lee SH, Kim SH, Wrangle J, Yang JC, Daga H, Juan Vidal OJ, Spira AI, Fernandez-Hinojal G, Kim SW, Umemura S, Provencio Pulla M, Keeton EK, Yang ZS, Li S, Xu ZC, Jones JA, Yu HA; REZILIENT1 Investigators. Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. **J Clin Oncol.** 2025 Jul 20;43(21):2387-2397. doi: 10.1200/JCO-25-00763. Epub 2025 Jun 1. PMID: 40450572.

10. Leighl NB, Trigo J, Park K, Lee SH, Girard N, Viteri S, Garrido P, Krebs MG, Thayu M, Knoblauch RE, Xie J, Bauml JM, Schnepf RW, Londhe A, Xia Y, Mahadevia PJ, Cho BC. Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer. **Lung Cancer.** 2025 Jul;205:108579. doi: 10.1016/j.lungcan.2025.108579. Epub 2025 May 10. PMID: 40446773.

11. Park S, Ahn HK, Lee S, Min YJ, Kim J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ, Lee JB, Lim SM, Kim HR, Cho BC, Hong MH. Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial. **J Thorac Oncol.** 2025 May 9:S1556-0864(25)00713-0. doi: 10.1016/j.jtho.2025.05.006. Epub ahead of print. PMID: 40350080.

12. Kim J, Kim MJ, Kim J, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Sun JM. Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small

Cell Lung Cancer. **Cancer Res Treat.** 2025 Apr 24. doi: 10.4143/crt.2024.1209. Epub ahead of print. PMID: 40302644.

13. Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhaskar K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S. Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset. **Lung Cancer.** 2025 Jun;204:108496. doi: 10.1016/j.lungcan.2025.108496. Epub 2025 Mar 15. PMID: 40300278.

14. Kang J, Lee JH, Cha H, An J, Kwon J, Lee S, Kim S, Baykan MY, Kim SY, An D, Kwon AY, An HJ, Lee SH, Choi JK, Park JE. Author Correction: Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types. **Nat Commun.** 2025 Mar 21;16(1):2806. doi: 10.1038/s41467-025-58068-y. Erratum for: Nat Commun. 2024 May 14;15(1):4067. doi: 10.1038/s41467-024-48310-4. PMID: 40118866; PMCID: PMC11928607.

15. Cho BC, Johnson M, Bar J, Schaefer E, Yoh K, Zer A, Moskovitz M, Lee SH, Moreno V, de Miguel M, Okuma Y, Kim JH, Lee CH, Peguero J, Ansell P, Biesdorf C, Saab R, Freise KJ, Ramies D, Jeng EE, Camidge DR. A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer. **Lung Cancer.** 2025 Apr;202:108492. doi: 10.1016/j.lungcan.2025.108492. Epub 2025 Mar 10. PMID: 40086026.

16. Jeong H, Koh J, Kim S, Yim J, Song SG, Kim H, Li Y, Lee SH, Chung YK, Kim H, Lee CH, Kim HY, Keam B, Lee SH, Chung DH, Jeon YK. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer. **J Immunother Cancer.** 2025 Mar 6;13(3):e010612. doi: 10.1136/jitc-2024-010612. PMID: 40050048; PMCID: PMC11887297.

17. Shin JE, Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Shim BY. Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer. **Sci Rep.** 2025 Feb 7;15(1):4593. doi: 10.1038/s41598-024-81704-4. PMID: 39920167; PMCID: PMC11805896.

18. Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, de Miguel MJ, Helissey C, Shu CA, Spira AI, Tomasini P, Yang JC, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on

Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSLIS-2 Cohort A. **J Thorac Oncol**. 2025 Jan 2:S1556-0864(24)02550-4. doi: 10.1016/j.jtho.2024.12.029. Epub ahead of print. PMID: 39755170.

19. Kim Y, Choi N, Kim EH, Chung MK, Son YI, Oh D, Ahn YC, [Lee SH](#), Jung HA, Park S, Kim J, Jeong HS, Ahn MJ. Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis. **Oncology**. 2024 Dec 23:1-11. doi: 10.1159/000543281. Epub ahead of print. PMID: 39715602.

20. [Sim H](#), [Park HJ](#), [Park GH](#), [Kim YJ](#), [Park WY](#), [Lee SH](#), [Choi M](#). Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden. **Elife**. 2024 Dec 6;13:RP96951. doi: 10.7554/eLife.96951. PMID: 39641768; PMCID: PMC11623926. [corresponding author]

21. Choi DH, Kim M, Kim YS, Park KU, Cho JH, Kim H, Lee KH, Ahn H, Kim IH, Lee KH, Lee GW, Yi SY, Ahn BC, Lee MY, Jung HA, Park S, Sun JM, Ahn JS, [Lee SH](#), Ahn MJ. Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18. **JTO Clin Res Rep**. 2024 Oct 16;5(12):100734. doi: 10.1016/j.jtocrr.2024.100734. PMID: 39619275; PMCID: PMC11605457.

22. Kim N, Park S, Jo A, Eum HH, Kim HK, Lee K, Cho JH, Ku BM, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Lee JI, Choi JW, Jeong D, Na M, Kang H, Kim JY, Choi JK, Lee HO, Ahn MJ. Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer. **Elife**. 2024 Nov 8;13:RP98366. doi: 10.7554/eLife.98366. PMID: 39514276; PMCID: PMC11548875.

23. Kim YG, Lee B, Ha C, Lee C, Jung HA, Sun JM, [Lee SH](#), Ahn MJ, Choi YL, Park S, Kim JW. Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer. **Front Oncol**. 2024 Oct 24;14:1463341. doi: 10.3389/fonc.2024.1463341. PMID: 39507756; PMCID: PMC11540554.

24. [Lee SH](#), Kim S, Lee J, Kim Y, Joo Y, Heo JY, Lee H, Lee C, Hwang GS, Park H. Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients. **Drug Resist Updat**. 2024 Nov;77:101159. doi: 10.1016/j.drug.2024.101159. Epub 2024 Oct 10. PMID: 39405736. [corresponding author]

25. Bak M, Park H, [Lee SH](#), Lee N, Ahn MJ, Ahn JS, Jung HA, Park S, Cho J, Kim J, Park SJ, Chang SA, Lee SC, Park SW, Kim EK. The Risk and Reversibility of Osimertinib-Related

Cardiotoxicity in a Real-World Population. **J Thorac Oncol**. 2024 Oct 10:S1556-0864(24)02377-3. doi: 10.1016/j.jtho.2024.10.003. Epub ahead of print. PMID: 39395664.

26. Kim HI, Kim WG, Kim M, Ko NG, Jin M, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, Jeon MJ, Kim TY, Kim WB, Kim SW, Lee DH, Jang SJ, Kim SW, Chung JH, Kim TH, [Lee SH](#). Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer. **Cancer Immunol Immunother**. 2024 Oct 9;73(12):260. doi: 10.1007/s00262-024-03852-w. PMID: 39382668; PMCID: PMC11479622. [[corresponding author](#)]

27. Kim T, Choe J, Shin SH, Jeong BH, Lee K, Kim H, [Lee SH](#), Um SW. Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib. **PLoS One**. 2024 Sep 19;19(9):e0310079. doi: 10.1371/journal.pone.0310079. PMID: 39298415; PMCID: PMC11412630.

28. Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, [Lee SH](#), Chen KN, Dooks C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. **Lancet**. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. PMID: 39288781.

29. Zhou C, Lu Y, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, [Lee SH](#), Chang J, Fang J, Liu Z, Bu L, Qian L, Xu T, Archer V, Hilton M, Zhou M, Zhang L. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced <i>ALK</i>-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study. **JTO Clin Res Rep**. 2024 Jun 27;5(9):100700. doi: 10.1016/j.jtocrr.2024.100700. PMID: 39282663; PMCID: PMC11399573.

30. Lee K, Cha H, Kim J, Jang Y, Son Y, Joe CY, Kim J, Kim J, [Lee SH](#), Lee S. Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma. **Sci Rep**. 2024 Sep 10;14(1):21096. doi: 10.1038/s41598-024-72108-5. PMID: 39256604; PMCID: PMC11387489. [[corresponding author](#)]

31. Jeon YK, Koh J, Lee D, Kim S, Song SG, Han B, Jeong H, Kim YA, Keam B, [Lee SH](#), Kim K, Chung DH. Spatially resolved whole-transcriptomic and proteomic profiling of lung cancer and its immune-microenvironment according to PD-L1 expression. **Cancer**

Immunol Res. 2024 Sep 5. doi: 10.1158/2326-6066.CIR-24-0071. Epub ahead of print. PMID: 39235761.

32. Jeong H, Koh J, Kim S, Song SG, Lee SH, Jeon Y, Lee CH, Keam B, Lee SH, Chung DH, Jeon YK. Correction: Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. **Br J Cancer.** 2024 Sep;131(4):779-780. doi: 10.1038/s41416-024-02798-1. Erratum for: Br J Cancer. 2024 Jul;131(1):23-36. doi: 10.1038/s41416-024-02698-4. PMID: 39080351; PMCID: PMC11333741.

33. Solomon BJ, Dagogo-Jack I, Lee SH, Boyer MJ, Ramalingam SS, Carcereny E, Felip E, Han JY, Hida T, Hughes BGM, Kim SW, Nishio M, Seto T, Okamoto T, Zhang X, Martini JF, Wang E, De Beukelaer S, Bauer TM. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial. **JTO Clin Res Rep.** 2024 May 16;5(7):100685. doi: 10.1016/j.jtocrr.2024.100685. PMID: 39034968; PMCID: PMC11260014.

34. Girard N, Park K, Lee SH, Viteri S, Schioppa CA, Diels J, Oguz M, Rodrigues BH, Rahhali N, Sermon J, Ghilotti F, Li T, Thayu M, Knoblauch RE, Mahadevia P, Cho BC. A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study. **Cancer Treat Res Commun.** 2024;40:100832. doi: 10.1016/j.ctarc.2024.100832. Epub 2024 Jul 9. PMID: 39033692.

35. Hochmair MJ, Vermaelen K, Mountzios G, Carcereny E, Doods C, Lee SH, Morocz E, Kato T, Ciuleanu TE, Dy GK, Parente B, O'Byrne KJ, Chu QS, Castro Junior G, Girard N, Snyder W, Tran Q, Kormany W, Houk B, Mehta B, Curioni-Fontecedro A. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. **Eur J Cancer.** 2024 Sep;208:114204. doi: 10.1016/j.ejca.2024.114204. Epub 2024 Jul 5. PMID: 39029295.

36. Jung YJ, Ahn J, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Cho SY, Jung HA. Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer. **Transl Cancer Res.** 2024 Jun 30;13(6):2587-2595. doi: 10.21037/tcr-23-2188. Epub 2024 Jun 27. PMID: 38988924; PMCID: PMC11231785.

37. Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhaskar K,

D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Amivantamab plus Lazertinib in Previously Untreated *EGFR*-Mutated Advanced NSCLC. **N Engl J Med**. 2024 Jun 26. doi: 10.1056/NEJMoa2403614. Epub ahead of print. PMID: 38924756.

38. Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, [Lee SH](#), Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Nahit Şendur MA, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory *EGFR*-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. **J Clin Oncol**. 2024 Jun 10;JCO2401001. doi: 10.1200/JCO.24.01001. Epub ahead of print. PMID: 38857463.

39. Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Bajjal S, Mansfield AS, Kuo CH, Nishino K, [Lee SH](#), Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous *EGFR*-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial. **J Clin Oncol**. 2024 Jun 6;JCO2400720. doi: 10.1200/JCO.24.00720. Epub ahead of print. PMID: 38843488.

40. Park S, Baldry R, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Kim YJ, Lee Y, Kim DW, Kim SW, Lee KH, Lee WJ, Choi JW, Chong K, Lee JI, Gwon SH, Son NH, Ahn MJ. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM). **J Clin Oncol**. 2024 Jun 3;JCO2400708. doi: 10.1200/JCO.24.00708. Epub ahead of print. PMID: 38828959.

41. Kang J, Lee JH, Cha H, An J, Kwon J, Lee S, Kim S, Baykan MY, Kim SY, An D, Kwon AY, An HJ, [Lee SH](#), Choi JK, Park JE. Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types. **Nat Commun**. 2024 May 14;15(1):4067. doi: 10.1038/s41467-024-48310-4. PMID: 38744958; PMCID: PMC11094150. [corresponding author]

42. Jeong H, Koh J, Kim S, Song SG, Lee SH, Jeon Y, Lee CH, Keam B, Lee SH, Chung DH, Jeon YK. Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. **Br J Cancer**. 2024 May 10. doi: 10.1038/s41416-024-02698-4. Epub ahead of print. PMID: 38729997.
43. Kim SY, Kim JH, Kim TY, Park SR, Yoon S, Lee S, Lee SH, Kim TM, Han SW, Kim HR, Yun H, Lee S, Kim J, Choi YL, Choi KS, Chae H, Ryu H, Lee GW, Zang DY, Ahn JB. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOREAN Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09. **BMC Cancer**. 2024 May 9;24(1):574. doi: 10.1186/s12885-024-12338-y. PMID: 38724991; PMCID: PMC11080169.
44. Kim H, Kim S, Choi S, Park C, Park S, Pereira S, Ma M, Yoo D, Paeng K, Jung W, Park S, Ock CY, Lee SH, Choi YL, Chung JH. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer. **JCO Precis Oncol**. 2024 May;8:e2300556. doi: 10.1200/PO.23.00556. PMID: 38723233.
45. Park JK, Jeong HO, Kim H, Choi JH, Lee EM, Kim S, Jang J, Choi DW, Lee SH, Kim KM, Jang KT, Lee KH, Lee KT, Lee MW, Lee JK, Lee S. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications. **Mol Cancer**. 2024 May 3;23(1):87. doi: 10.1186/s12943-024-02003-0. PMID: 38702773; PMCID: PMC11067162.
46. Shin J, Park S, Kim KH, Shin EC, Jung HA, Cho JH, Sun JM, Lee SH, Choi YS, Ahn JS, Kim J, Park K, Shim YM, Kim HK, Noh JM, Ahn YC, Pyo H, Ahn MJ. Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial. **Cancer Res Treat**. 2024 Apr 30. doi: 10.4143/crt.2024.084. Epub ahead of print. PMID: 38697848.
47. Boumelha J, de Castro A, Bah N, Cha H, de Carné Trécesson S, Rana S, Tomaschko M, Anastasiou P, Mugarza E, Moore C, Goldstone R, East P, Litchfield K, Lee SH, Molina-Arcas M, Downward J. CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer. **Cancer Res**. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2627. Epub ahead of print. PMID: 38635884.

48. Park S, Kang JK, Lee N, [Lee SH](#), Kim HP, Kim SY, Kim TY, Kim H, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K. Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses. **Transl Lung Cancer Res.** 2024 Feb 29;13(2):280-291. doi: 10.21037/tlcr-23-479. Epub 2024 Feb 23. PMID: 38496698; PMCID: PMC10938094. [corresponding author]
49. Jung HA, Park B, Park S, Sun JM, [Lee SH](#), Seok Ahn J, Ahn MJ. Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis. **Lung Cancer.** 2024 Apr;190:107536. doi: 10.1016/j.lungcan.2024.107536. Epub 2024 Mar 13. PMID: 38493759.
50. Park S, Hong TH, Hwang S, Heeke S, Gay CM, Kim J, Jung HA, Sun JM, Ahn JS, Ahn MJ, Cho JH, Choi YS, Kim J, Shim YM, Kim HK, Byers LA, Heymach JV, Choi YL, [Lee SH](#), Park K. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. **EBioMedicine.** 2024 Apr;102:105062. doi: 10.1016/j.ebiom.2024.105062. Epub 2024 Mar 15. PMID: 38492534; PMCID: PMC10959651. [corresponding author]
51. Jeon Y, Park S, [Lee SH](#), Kim TH, Kim SW, Ahn MJ, Jung HA, Chung JH. Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer. **Cancer Res Treat.** 2024 Mar 6. doi: 10.4143/crt.2023.1278. Epub ahead of print. PMID: 38453274.
52. Kim H, Jang J, Choi JH, Song JH, [Lee SH](#), Park J, Ryoo SK, Lee EM, Jeong HO, Kim S, Lee SH, Lee KH, Lee KT, Kim KM, Jang KT, Lee H, Lee S, Lee JK, Park JK. Establishment of a patient-specific avatar organoid model derived from EUS- guided fine-needle biopsy for timely clinical application in pancreatic ductal adenocarcinoma (with video). **Gastrointest Endosc.** 2024 Jul;100(1):85-96.e9. doi: 10.1016/j.gie.2024.02.021. Epub 2024 Mar 4. PMID: 38447660.
53. Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, Bogdan S, Huang M, Fisher GA, Park S, [Lee SH](#), Hwang JE, Chung JH, Kim L, Song H, Pereira S, Shin S, Lim Y, Ahn CH, Kim S, Oum C, Kim S, Park G, Song S, Jung W, Kim S, Bang YJ, Mok TSK, Ali SM, Ock CY. Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. **J Immunother Cancer.** 2024 Feb 14;12(2):e008339. doi: 10.1136/jitc-2023-008339. PMID: 38355279; PMCID: PMC10868175.
54. Hwang S, Hong TH, Kim HK, Cho J, Lee G, Choi S, Park S, [Lee SH](#), Lee Y, Jeon YJ, Lee J, Park SY, Cho JH, Choi YS, Kim J, Zo JI, Shim YM, Choi YL. PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC

grading system. **Histopathology**. 2024 Jan 30. doi: 10.1111/his.15146. Epub ahead of print. PMID: 38288635.

55. Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, [Lee SH](#), Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. **J Clin Oncol**. 2024 Jan 22;JCO2301017. doi: 10.1200/JCO.23.01017. Epub ahead of print. PMID: 38252907.

56. Choi DH, Jung HA, Park S, Sun JM, Ahn JS, Ahn MJ, [Lee SH](#). Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC). **Transl Lung Cancer Res**. 2023 Dec 26;12(12):2448-2459. doi: 10.21037/tlcr-23-643. Epub 2023 Dec 22. PMID: 38205202; PMCID: PMC10775014. [corresponding author]

57. Seo SH, Pyo H, Ahn YC, Oh D, Yang K, Kim N, Sun JM, Park S, Jung HA, [Lee SH](#), Ahn JS, Ahn MJ, Noh JM. Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer. **Radiat Oncol J**. 2023 Dec;41(4):274-282. doi: 10.3857/roj.2023.00773. Epub 2023 Dec 6. PMID: 38185932; PMCID: PMC10772597.

58. Hong J, Lee J, Park S, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Sinn DH, Ahn MJ. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B. **Cancer**. 2024 Jan 2. doi: 10.1002/cncr.35175. Epub ahead of print. PMID: 38165808.

59. Song S, Koh Y, Kim S, Lee SM, Kim HU, Ko JM, [Lee SH](#), Yoon SS, Park S. Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes. **Genome Med**. 2023 Dec 25;15(1):107. doi: 10.1186/s13073-023-01252-w. PMID: 38143269; PMCID: PMC10749499. [corresponding author]

60. Kim K, Kim H, Shin I, Noh SJ, Kim JY, Suh KJ, Kim YN, Lee JY, Cho DY, Kim SH, Kim JH, [Lee SH](#), Choi JK. Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer. **Sci Rep**. 2023 Dec 18;13(1):22482. doi: 10.1038/s41598-023-49639-4. PMID: 38110532; PMCID: PMC10728099. [corresponding author]

61. Jun S, Park S, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ, Cho J, Jung HA. Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable

Genetic Alterations. **Cancers (Basel)**. 2023 Nov 16;15(22):5450. doi: 10.3390/cancers15225450. PMID: 38001710; PMCID: PMC10670305.

62. Kim SY, Jeong S, Lee W, Jeon Y, Kim YJ, Park S, Lee D, Go D, Song SH, Lee S, Woo HG, Yoon JK, Park YS, Kim YT, Lee SH, Kim KH, Lim Y, Kim JS, Kim HP, Bang D, Kim TY. Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection. **Exp Mol Med**. 2023 Nov 1. doi: 10.1038/s12276-023-01119-5. Epub ahead of print. PMID: 37907748.

63. Ang YLE, Zhao X, Reungwetwattana T, Cho BC, Liao BC, Yeung R, Loong HH, Kim DW, Yang JC, Lim SM, Ahn MJ, Lee SH, Suwatanapongched T, Kongchaug K, Ou Q, Yu R, Tai BC, Goh BC, Mok TSK, Soo RA. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study). **Cancers (Basel)**. 2023 Oct 16;15(20):4999. doi: 10.3390/cancers15204999. PMID: 37894366; PMCID: PMC10605750.

64. Lee H, Seo S, Won S, Park WY, Choi JY, Lee KH, Lee SH, Moon SH. Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients. **Sci Rep**. 2023 Oct 25;13(1):18247. doi: 10.1038/s41598-023-45296-9. PMID: 37880322; PMCID: PMC10600181.

65. Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATLAS, KCSG-LU19-04). **J Clin Oncol**. 2023 Oct 20;101200JCO2301891. doi: 10.1200/JCO.23.01891. Epub ahead of print. PMID: 37861993.

66. Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Sun JM. Real-world clinical evidence of lazertinib use in acquired *EGFR* T790M mutated non-small cell lung cancer. **Transl Lung Cancer Res**. 2023 Sep 28;12(9):1912-1922. doi: 10.21037/tlcr-23-160. Epub 2023 Aug 22. PMID: 37854157; PMCID: PMC10579823.

67. Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, Clark J, Koivunen JP, Macherla S, Jonnalagadda S, Polsani S, Jiwani RA, Hafiz M, Muzaffar M, Brunetti L, Stroud CRG, Walker PR, Wang K, Chung Y, Ruppin E, Lee SH, Yang LV, Pinato DJ, Lee JS, Cortellini A. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. **J**

Immunother Cancer. 2023 Oct;11(10):e007310. doi: 10.1136/jitc-2023-007310. PMID: 37852738; PMCID: PMC10603340.

68. Koh Y, Kim H, Joo SY, Song S, Choi YH, Kim HR, Moon B, Byun J, Hong J, Shin DY, Park S, Lee KH, Lee KT, Lee JK, Park D, [Lee SH](#), Jang JY, Lee H, Kim JA, Yoon SS, Park JK. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. **J Transl Med.** 2023 Oct 17;21(1):730. doi: 10.1186/s12967-023-04549-x. PMID: 37848935; PMCID: PMC10580633.

69. Park S, Kim YJ, Min YJ, Mortimer PGS, Kim HJ, Smith SA, Dean E, Jung HA, Sun JM, Park WY, Ahn JS, Ahn MJ, [Lee SH](#), Park K. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. **Cancer.** 2023 Oct 16. doi: 10.1002/cncr.35059. Epub ahead of print. PMID: 37843249. [corresponding author]

70. Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, [Lee SH](#), Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Jänne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. **J Clin Oncol.** 2023 Sep 10;JCO2301476. doi: 10.1200/JCO.23.01476. Epub ahead of print. PMID: 37689979.

71. Hong TH, Bang YH, Joe C, Choi YL, [Lee SH](#). Comment on "Leveraging NGS Data to Refine Immunotherapy Response Prediction in NSCLC: PD-L1 Copy Number, Tumor Mutation Burden, and Beyond". **J Thorac Oncol.** 2023 Sep;18(9):e88-e90. doi: 10.1016/j.jtho.2023.05.023. PMID: 37599051. [corresponding author]

72. Choi SW, Jung HA, Cho HJ, Kim TM, Park CK, Nam DH, [Lee SH](#). A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification. **Cancer Med.** 2023 Aug;12(15):15788-15796. doi: 10.1002/cam4.6213. Epub 2023 Aug 3. PMID: 37537946; PMCID: PMC10469652. [corresponding author]

73. Jeon Y, Park S, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ. First-Line Alectinib vs. Brigatinib in Advanced NSCLC with ALK Rearrangement: Real-World Data. **Cancer Res Treat.** 2023 Jul 14. doi: 10.4143/crt.2023.461. Epub ahead of print. PMID: 37448121.

74. Jung HA, Ku BM, Kim YJ, Park S, Sun JM, [Lee SH](#), Ahn JS, Cho JH, Kim HK, Choi YS, Choi YL, Shin SH, Jeong BH, Um SW, Kim H, Kim K, Ahn MJ, Kim J. Longitudinal

Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer. **J Thorac Oncol.** 2023 Sep;18(9):1199-1208. doi: 10.1016/j.jtho.2023.05.027. Epub 2023 Jun 10. PMID: 37308037.

75. Wakelee H, Liberman M, Kato T, Tsuboi M, [Lee SH](#), Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. **N Engl J Med.** 2023 Jun 3. doi: 10.1056/NEJMoa2302983. Epub ahead of print. PMID: 37272513.

76. Lee J, Park S, Jung HA, [Lee SH](#), Seo S, Kim SB, Kim JW, Lee KW, Kang EJ, Kim JW, Choi YJ, Shim BY, An HJ, Park LC, Shin SH, Kim JJ, Oh SY, Kim MK, Ahn MJ. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. **Cancer.** 2023 May 28. doi: 10.1002/cncr.34892. Epub ahead of print. PMID: 37246414.

77. Jeon Y, Jung HA, Park S, Sun JM, Ahn JS, Ahn MJ, Park K, [Lee SH](#). Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement. **Cancer Res Treat.** 2023 May 22. doi: 10.4143/crt.2023.403. Epub ahead of print. PMID: 37218138. [corresponding author]

78. Kim H, Park S, Jung HA, [Lee SH](#), Park K, Ahn YC, Oh D, Ahn MJ. Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. **Cancer Res Treat.** 2023 May 17. doi: 10.4143/crt.2023.502. Epub ahead of print. PMID: 37202212.

79. [Lee SH](#), Kim Y, Jeon BN, Kim G, Sohn J, Yoon Y, Kim S, Kim Y, Kim H, Cha H, Lee NE, Yang H, Chung JY, Jeong AR, Kim YY, Kim SG, Seo Y, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park H, Yoon KW. Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8⁺ T Cells. **Adv Sci (Weinh).** 2023 Jun;10(17):e2204378. doi: 10.1002/adv.202204378. Epub 2023 Apr 25. PMID: 37097643; PMCID: PMC10265102. [first author]

80. Hwang S, Hong TH, Kim HK, Choi YS, Zo JI, Shim YM, Han J, Chan Ahn Y, Pyo H, Noh JM, Lee HY, Kim HJ, Park S, Ahn MJ, Park K, [Lee SH](#), Choi YL, Kim J. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance. **Mod Pathol.** 2023 Apr 11;36(7):100184. doi: 10.1016/j.modpat.2023.100184. Epub ahead of print. PMID: 37054974. [corresponding author]

81. Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M, Young G, Molina-Arcas M, de Carné Trécesson S, Anastasiou P, Fendler A, Au L, Shepherd STC, Martínez-Ruiz C, Puttick C, Black JRM, Watkins TBK, Kim H, Shim S, Faulkner N, Attig J, Veeriah S, Magno N, Ward S, Frankell AM, Al Bakir M, Lim EL, Hill MS, Wilson GA, Cook DE, Birkbak NJ, Behrens A, Yousaf N, Popat S, Hackshaw A; TRACERx Consortium; CAPTURE Consortium; Hiley CT, Litchfield K, McGranahan N, Jamal-Hanjani M, Larkin J, [Lee SH](#), Turajlic S, Swanton C, Downward J, Kassiotis G. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. **Nature**. 2023 Apr;616(7957):563-573. doi: 10.1038/s41586-023-05771-9. Epub 2023 Apr 12. PMID: 37046094; PMCID: PMC10115647.

82. Hong TH, Bang YH, Joe C, Hwang S, Lee B, Lee N, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, [Lee SH](#). Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer. **J Thorac Oncol**. 2023 Apr 5:S1556-0864(23)00482-3. doi: 10.1016/j.jtho.2023.03.024. Epub ahead of print. PMID: 37028596. [corresponding author]

83. Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, Kuan FC, Marongiu F, Evans EJ Jr, Moore DA, Rodrigues FS, Pich O, Bakker B, Cha H, Myers R, van Maldegem F, Boumelha J, Veeriah S, Rowan A, Naceur-Lombardelli C, Karasaki T, Sivakumar M, De S, Caswell DR, Nagano A, Black JRM, Martínez-Ruiz C, Ryu MH, Huff RD, Li S, Favé MJ, Magness A, Suárez-Bonnet A, Priestnall SL, Lüchtenborg M, Lavelle K, Pethick J, Hardy S, McDonald FE, Lin MH, Troccoli CI, Ghosh M, Miller YE, Merrick DT, Keith RL, Al Bakir M, Bailey C, Hill MS, Saal LH, Chen Y, George AM, Abbosh C, Kanu N, [Lee SH](#), McGranahan N, Berg CD, Sasieni P, Houlston R, Turnbull C, Lam S, Awadalla P, Grönroos E, Downward J, Jacks T, Carlsten C, Malanchi I, Hackshaw A, Litchfield K; TRACERx Consortium; DeGregori J, Jamal-Hanjani M, Swanton C. Lung adenocarcinoma promotion by air pollutants. **Nature**. 2023 Apr;616(7955):159-167. doi: 10.1038/s41586-023-05874-3. Epub 2023 Apr 5. PMID: 37020004.

84. Chi SA, Yu H, Choi YL, Park S, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ, Choi DH, Kim K, Jung HA, Park K. Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. **JAMA Netw Open**. 2023 Mar 1;6(3):e232002. doi: 10.1001/jamanetworkopen.2023.2002. PMID: 36929402; PMCID: PMC1002088

85. Kim H, Park S, Han KY, Lee N, Kim H, Jung HA, Sun JM, Ahn JS, Ahn MJ, [Lee SH](#), Park WY. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment. **J Immunother**

Cancer. 2023 Feb;11(2):e005509. doi: 10.1136/jitc-2022-005509. PMID: 36787939; PMCID: PMC9930609. [corresponding author]

86. Park C, Jeong DY, Choi Y, Oh YJ, Kim J, Ryu J, Paeng K, [Lee SH](#), Ock CY, Lee HY. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. **Front Immunol.** 2023 Jan 5;13:1038089. doi: 10.3389/fimmu.2022.1038089. PMID: 36660547; PMCID: PMC9844154.

87. Kim JE, Kim H, Kim B, Chung HG, Chung HH, Kim KM, Kim SH, Jeong WK, Kim YK, Min JH, Heo JS, Han IW, Shin SH, Park HC, Yu JI, Park JO, Kim ST, Hong JY, [Lee SH](#), Lee KH, Lee JK, Lee KT, Jang KT, Park JK. Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers. **Cancer Med.** 2023 Jan 17. doi: 10.1002/cam4.5530. Epub ahead of print. PMID: 36650632.

88. Kim JY, Cha H, Kim K, Sung C, An J, Bang H, Kim H, Yang JO, Chang S, Shin I, Noh SJ, Shin I, Cho DY, [Lee SH](#), Choi JK. MHC II immunogenicity shapes the neoepitope landscape in human tumors. **Nat Genet.** 2023 Jan 9. doi: 10.1038/s41588-022-01273-y. Epub ahead of print. PMID: 36624345. [corresponding author]

89. Jung HA, Park S, [Lee SH](#), Ahn JS, Ahn MJ, Sun JM. The Role of Brain Radiotherapy Before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. **Cancer Res Treat.** 2022 Dec 27. doi: 10.4143/crt.2022.1344. Epub ahead of print. PMID: 36596729.

90. Park S, Cha H, Kim HS, Lee B, Kim S, Kim TM, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, [Lee SH](#). Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. **Cancer Med.** 2022 Dec 1. doi: 10.1002/cam4.5460. Epub ahead of print. PMID: 36453453. [corresponding author]

91. Jeong HO, Lee H, Kim H, Jang J, Kim S, Hwang T, Choi DW, Kim HS, Lee N, Lee YM, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee S, [Lee SH](#). Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma. **iScience.** 2022 Oct 13;25(11):105358. doi: 10.1016/j.isci.2022.105358. PMID: 36339256; PMCID: PMC9626676. [corresponding author]

92. Jung HA, Kim M, Kim HS, Kim JH, Choi YH, Cho J, Park JH, Park KU, Ku BM, Park S, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21). **J Thorac Oncol.** 2022 Oct

25:S1556-0864(22)01858-5. doi: 10.1016/j.jtho.2022.10.008. Epub ahead of print. PMID: 36307042.

93. Lee MS, An S, Song JY, Sung M, Jung K, Chang ES, Choi J, Oh DY, Jeon YK, Yang H, Lakshmi C, Park S, Han J, [Lee SH](#), Choi YL. Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma. **Cancer Res Treat**. 2022 Oct 14. doi: 10.4143/crt.2022.910. Epub ahead of print. PMID: 36265509.

94. Kim H, Park S, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ. EGFR Mutation Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis. **Cancer Res Treat**. 2022 Oct 4. doi: 10.4143/crt.2022.388. Epub ahead of print. PMID: 36228655.

95. Kwon HR, Cho J, Park S, [Lee SH](#), Ahn MJ, Choi JY, Lee KH, Jung HA, Moon SH. Metabolic parameters on baseline ¹⁸F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma. **Front Med (Lausanne)**. 2022 Sep 26;9:896494. doi: 10.3389/fmed.2022.896494. PMID: 36226146; PMCID: PMC9548588.

96. Hur JY, Ku BM, Park S, Jung HA, [Lee SH](#), Ahn MJ. Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma. **PLoS One**. 2022 Oct 6;17(10):e0274830. doi: 10.1371/journal.pone.0274830. PMID: 36201479; PMCID: PMC9536544.

97. Roh W, Geffen Y, Cha H, Miller M, Anand S, Kim J, Heiman DI, Gainor JF, Laird PW, Cherniack AD, Ock CY, [Lee SH](#), Getz G. High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. **Cancer Res**. 2022 Aug 30;CAN-22-0432. doi: 10.1158/0008-5472.CAN-22-0432. Epub ahead of print. PMID: 36040373. [corresponding author]

98. Koh J, Kim S, Woo YD, Song SG, Yim J, Han B, Lim S, Ahn HK, Mun S, Kim JS, Keam B, Kim YA, [Lee SH](#), Jeon YK, Chung DH. TCF1⁺PD-1⁺ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer. **Eur J Cancer**. 2022 Aug 12;174:10-20. doi: 10.1016/j.ejca.2022.07.004. Epub ahead of print. PMID: 35970031.

99. Kim KH, Pyo H, Lee H, Oh D, Noh JM, Ahn YC, Kim CG, Yoon HI, Lee J, Park S, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Park K, Ku BM, Shin EC, Ahn MJ. Association of T cell senescence with radiation pneumonitis in patients with non-small cell lung cancer. **Int J**

Radiat Oncol Biol Phys. 2022 Jul 24:S0360-3016(22)00737-4. doi: 10.1016/j.ijrobp.2022.07.018. Epub ahead of print. PMID: 35896144.

100. Jung HA, Lim J, Choi YL, Lee SH, Joung JG, Jeon YJ, Choi JW, Shin S, Cho JH, Kim HK, Choi YS, Zo JI, Shim YM, Park S, Sun JM, Ahn JS, Ahn MJ, Han J, Park WY, Kim J, Park K. Clinical, pathological, and molecular prognostic factors in patients with early-stage EGFR mutant NSCLC. **Clin Cancer Res.** 2022 Jul 15:CCR-22-0879. doi: 10.1158/1078-0432.CCR-22-0879. Epub ahead of print. PMID: 35838647.

101. Choi S, Cho SI, Ma M, Park S, Pereira S, Aum BJ, Shin S, Paeng K, Yoo D, Jung W, Ock CY, Lee SH, Choi YL, Chung JH, Mok TS, Kim H, Kim S. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response. **Eur J Cancer.** 2022 Jul;170:17-26. doi: 10.1016/j.ejca.2022.04.011. Epub 2022 May 14. PMID: 35576849.

102. Park S, Noh JM, Choi YL, Chi SA, Kim K, Jung HA, Lee SH, Ahn JS, Ahn MJ, Sun JM. Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. **Eur J Cancer.** 2022 Jul;169:42-53. doi: 10.1016/j.ejca.2022.03.034. Epub 2022 Apr 29. PMID: 35500460.

103. Kwon M, Ku BM, Olsen S, Park S, Lefterova M, Odegaard J, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. **Cancer Med.** 2022 Apr 19. doi: 10.1002/cam4.4663. Epub ahead of print. PMID: 35437925.

104. Lee J, Koh J, Kim HK, Hong S, Kim K, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. **J Thorac Oncol.** 2022 Jul;17(7):900-908. doi: 10.1016/j.jtho.2022.04.001. Epub 2022 Apr 12. PMID: 35427805.

105. Kim HR, Jo H, Kim H, Hong J, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ. Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. **Cancer Res Treat.** 2022 Mar 28. doi: 10.4143/crt.2021.1603. Epub ahead of print. PMID: 35344648.

106. Park S, Ock CY, Kim H, Pereira S, Park S, Ma M, Choi S, Kim S, Shin S, Aum BJ, Paeng K, Yoo D, Cha H, Park S, Suh KJ, Jung HA, Kim SH, Kim YJ, Sun JM, Chung JH, Ahn JS, Ahn MJ, Lee JS, Park K, Song SY, Bang YJ, Choi YL, Mok TS, [Lee SH](#). Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. **J Clin Oncol**. 2022 Mar 10;JCO2102010. doi: 10.1200/JCO.21.02010. Epub ahead of print. PMID: 35271299. [corresponding author]

107. Ku BM, Kim YJ, Park D, [Lee SH](#), Ahn JS, Park K, Ahn MJ, Sun JM. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor. **Oncology**. 2022 Feb 23;1-10. doi: 10.1159/000516813. Epub ahead of print. PMID: 35196661.

108. Kim KH, Pyo H, Oh HLD, Noh JM, Ahn YC, Yoon HI, Moon H, Lee J, Park S, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Park K, Ku BM, Ahn MJ, Shin EC. Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy. **Int J Radiat Oncol Biol Phys**. 2022 Feb 9;S0360-3016(22)00143-2. doi: 10.1016/j.ijrobp.2022.02.003. Epub ahead of print. PMID: 35150786.

109. Jung HA, Park S, Choi YL, [Lee SH](#), Ahn JS, Ahn MJ, Sun JM. Continuation of pembrolizumab with additional chemotherapy after progression with PD-1/PD-L1 inhibitor monotherapy in patients with advanced NSCLC. **Clin Cancer Res**. 2022 Jan 31;clincanres.3646.2021. doi: 10.1158/1078-0432.CCR-21-3646. Epub ahead of print. PMID: 35101883.

110. Lee YP, Jung HA, Lee MS, Choi JW, Kong DS, Seol HJ, Nam DH, Lee JI, [Lee SH](#). Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. **J Neurooncol**. 2022 Feb;156(3):541-549. doi: 10.1007/s11060-021-03930-4. Epub 2022 Jan 30. PMID: 35094201.

111. Hwang S, Hong TH, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YL, [Lee SH](#). Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. **Transl Lung Cancer Res**. 2021 Nov;10(11):4209-4220. doi: 10.21037/tlcr-21-691. PMID: 35004251; PMCID: PMC8674595. [corresponding author]

112. Cao Y, Qin S, Luo S, Li Z, Cheng Y, Fan Y, Sun Y, Yin X, Yuan X, Li W, Liu T, Hsu CH, Lin X, Kim SB, Kojima T, Zhang J, [Lee SH](#), Bai Y, Muro K, Doi T, Bai C, Gu K, Pan HM, Bai L, Yang JW, Cui Y, Lu W, Chen J. Pembrolizumab versus chemotherapy for patients with

esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia. **ESMO Open**. 2022 Feb;7(1):100341. doi: 10.1016/j.esmoop.2021.100341. Epub 2021 Dec 29. PMID: 34973513; PMCID: PMC8764510.

113. Ku BM, Heo JY, Kim J, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer. **Invest New Drugs**. 2022 Jan 1. doi: 10.1007/s10637-021-01121-6. Epub ahead of print. PMID: 34973117.

114. Kim H, Lee HY, [Lee SH](#), Lee IS, Choi JY, Shim YM. The rarest of rare cases within the one thousand faces of atypical carcinoid: Pseudomesotheliomatous manifestation in a pregnant woman. **Thorac Cancer**. 2022 Feb;13(4):643-647. doi: 10.1111/1759-7714.14297. Epub 2021 Dec 30. PMID: 34970830; PMCID: PMC8841698.

115. Park JG, Choi BK, Lee Y, Jang EJ, Woo SM, Lee JH, Kim KH, Hwang H, Choi W, [Lee SH](#), Yoo BC. Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. **EPMA J**. 2021 Nov 25;12(4):629-645. doi: 10.1007/s13167-021-00266-x. PMID: 34956427; PMCID: PMC8648880. [corresponding author]

116. Kim H, Heo CM, Oh J, Chung HH, Lee EM, Park J, [Lee SH](#), Lee KH, Lee KT, Lee JK, Cho YK, Park JK. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. **Transl Oncol**. 2022 Feb;16:101321. doi: 10.1016/j.tranon.2021.101321. Epub 2021 Dec 23. PMID: 34954457; PMCID: PMC8718659.

117. Song C, Park H, Lee HY, Lee S, Ahn JH, [Lee SH](#). Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach. **Cancers (Basel)**. 2021 Dec 1;13(23):6050. doi: 10.3390/cancers13236050. PMID: 34885160; PMCID: PMC8657103.

118. Jung HA, Jeong O, Chang DK, Park S, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ, Park K. Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. **Transl Lung Cancer Res**. 2021 Oct;10(10):3865-3874. doi: 10.21037/tlcr-21-531. PMID: 34858777; PMCID: PMC8577969.

119. Lee YP, Jeong BH, Eun Y, Kang CI, Park S, Jung HA, [Lee SH](#), Ahn JS, Ahn MJ, Park K, Sun JM. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. **Eur J Cancer**. 2021 Dec;159:167-173. doi: 10.1016/j.ejca.2021.09.037. Epub 2021 Nov 6. PMID: 34753013.

120. Kim HR, Lee SJ, Park S, Jung HA, Lee SH, Jeong HS, Chung MK, Ahn MJ. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer. **Cancer Res Treat.** 2021 Nov 1. doi: 10.4143/crt.2021.1019. Epub ahead of print. PMID: 34727492.

121. Choi Y, Aum J, Lee SH, Kim HK, Kim J, Shin S, Jeong JY, Ock CY, Lee HY. Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma. **Cancers (Basel).** 2021 Aug 13;13(16):4077. doi: 10.3390/cancers13164077. PMID: 34439230; PMCID: PMC8391458.

122. Park JK, Kim H, Son DS, Kim NKD, Sung YK, Cho M, Lee C, Noh DH, Lee SH, Lee KT, Lee JK, Jang KT, Park WY, Lee KH. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. **Cancers (Basel).** 2021 Jun 3;13(11):2791. doi: 10.3390/cancers13112791. PMID: 34205170; PMCID: PMC8199936.

123. Koh J, Kim S, Lee SN, Kim SY, Kim JE, Lee KY, Kim MS, Heo JY, Park YM, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Yang S, Ha SJ, Lim YT, Ahn MJ. Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. **Nanomedicine.** 2021 Jun 24;37:102415. doi: 10.1016/j.nano.2021.102415. Epub ahead of print. PMID: 34174421.

124. Kim C, Cho HH, Choi JY, Franks TJ, Han J, Choi Y, Lee SH, Park H, Lee KS. Pleomorphic carcinoma of the lung: Prognostic models of semantic, radiomics and combined features from CT and PET/CT in 85 patients. **Eur J Radiol Open.** 2021 May 18;8:100351. doi: 10.1016/j.ejro.2021.100351. PMID: 34041307; PMCID: PMC8141891.

125. Kim H, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Long-Term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. **Cancer Res Treat.** 2021 May 6. doi: 10.4143/crt.2021.306. Epub ahead of print. PMID: 33957020.

126. Moon J, Kim MS, Kim YZ, Hwang K, Park JE, Kim KH, Cho JM, Yoon WS, Kim SH, Kim YI, Kim HS, Dho YS, Park JS, Yoon HI, Seo Y, Sung KS, Song JH, Wee CW, Lee MH, Han MH, Hong JB, Im JH, Lee SH, Chang JH, Lim DH, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group. The Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage of Brain Tumor: Version 2021.1. **Brain Tumor Res Treat.** 2021 Apr;9(1):9-15. doi: 10.14791/btrt.2021.9.e7. PMID: 33913266; PMCID: PMC8082286.

127. Yoon HI, Wee CW, Kim YZ, Seo Y, Im JH, Dho YS, Kim KH, Hong JB, Park JS, Choi SH, Kim MS, Moon J, Hwang K, Park JE, Cho JM, Yoon WS, Kim SH, Kim YI, Kim HS, Sung KS, Song JH, Lee MH, Han MH, Lee SH, Chang JH, Lim DH, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1. **Brain Tumor Res Treat.** 2021 Apr;9(1):1-8. doi: 10.14791/btrt.2021.9.e8. PMID: 33913265; PMCID: PMC8082289.
128. Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E. Synthetic lethality-mediated precision oncology via the tumor transcriptome. **Cell.** 2021 Apr 29;184(9):2487-2502.e13. doi: 10.1016/j.cell.2021.03.030. Epub 2021 Apr 14. PMID: 33857424.
129. Park J, Jung HA, Shim JH, Park WY, Kim TH, Lee SH, Kim SW, Ahn MJ, Park K, Chung JH. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. **Eur J Endocrinol.** 2021 May 6;184(6):837-845. doi: 10.1530/EJE-20-1482. PMID: 33852431.
130. Park S, Olsen S, Ku BM, Lee MS, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Ahn MJ. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. **Cancer.** 2021 Aug 15;127(16):3019-3028. doi: 10.1002/cncr.33571. Epub 2021 Apr 7. PMID: 33826761.
131. Kim H, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. **Transl Lung Cancer Res.** 2021 Feb;10(2):878-888. doi: 10.21037/tlcr-20-1128. PMID: 33718029; PMCID: PMC7947405.
132. Kim KH, Hur JY, Koh J, Cho J, Ku BM, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC. Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. **Immune Netw.** 2020 Dec 21;20(6):e48. doi: 10.4110/in.2020.20.e48. PMID: 33425433; PMCID: PMC7779871.
133. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assunção JA, Conde L, Furness AJS, Saini SK, Hadrup SR, Herrero J, Lee SH, Van Loo P, Enver T, Larkin J, Hellmann MD, Turajlic S, Quezada SA, McGranahan N, Swanton C. Meta-analysis of tumor- and T

cell-intrinsic mechanisms of sensitization to checkpoint inhibition. **Cell**. 2021 Feb 4;184(3):596-614.e14. doi: 10.1016/j.cell.2021.01.002. Epub 2021 Jan 27. PMID: 33508232.

134. Ku BM, Kim Y, Lee KY, Kim SY, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. **Eur J Immunol**. 2021 Jan 28. doi: 10.1002/eji.202048966. Epub ahead of print. PMID: 33506525.

135. [Lee SH](#), Cho SY, Yoon Y, Park C, Sohn J, Jeong JJ, Jeon BN, Jang M, An C, Lee S, Kim YY, Kim G, Kim S, Kim Y, Lee GB, Lee EJ, Kim SG, Kim HS, Kim Y, Kim H, Yang HS, Kim S, Kim S, Chung H, Moon MH, Nam MH, Kwon JY, Won S, Park JS, Weinstock GM, Lee C, Yoon KW, Park H. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. **Nat Microbiol**. 2021 Jan 11. doi: 10.1038/s41564-020-00831-6. Epub ahead of print. PMID: 33432149. [first author]

136. Kim JY, Jeong HO, Heo DS, Keam B, Moon KC, Kwak C, Jang J, Kim S, Kim JI, Lee S, [Lee SH](#). Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. **Ann Transl Med**. 2020 Nov;8(21):1389. doi: 10.21037/atm-20-3466. PMID: 33313134; PMCID: PMC7723617. [corresponding author]

137. Lee MH, Cho KR, Choi JW, Kong DS, Seol HJ, Nam DH, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ, Park K, Lee JI. Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. **J Korean Neurosurg Soc**. 2020 Dec 4. doi: 10.3340/jkns.2020.0135. Epub ahead of print. PMID: 33267531.

138. Park C, Jeong K, Park JH, Jung S, Bae JM, Kim K, Ock CY, Kim M, Keam B, Kim TM, Jeon YK, [Lee SH](#), Lee JS, Kim DW, Kang GH, Chung DH, Heo DS. Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. **Cancer Immunol Immunother**. 2020 Nov 24. doi: 10.1007/s00262-020-02796-1. Epub ahead of print. PMID: 33230567.

139. Jung HA, Woo SY, [Lee SH](#), Ahn JS, Ahn MJ, Park K, Sun JM. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. **Transl Lung Cancer Res**. 2020 Oct;9(5):1749-1758. doi: 10.21037/tlcr-20-379. PMID: 33209598; PMCID: PMC7653133.

140. Koh J, Hur JY, Lee KY, Kim MS, Heo JY, Ku BM, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Regulatory FoxP3+ T cells and TGF- β predict the response to anti-PD-1

immunotherapy in patients with non-small cell lung cancer. **Sci Rep.** 2020 Nov 4;10(1):18994. doi: 10.1038/s41598-020-76130-1. PMID: 33149213; PMCID: PMC7642363.

141. Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, Ahn MJ, Park K, [Lee SH](#), Park WY. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. **J Immunother Cancer.** 2020 Oct;8(2):e001199. doi: 10.1136/jitc-2020-001199. PMID: 33077514; PMCID: PMC7574938. [[corresponding author](#)]

142. Jung HA, Park S, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ, Park K. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon *EGFR* Mutations: Are They Different from Those with Common *EGFR* Mutations? **Biology (Basel).** 2020 Oct 7;9(10):E326. doi: 10.3390/biology9100326. PMID: 33036377.

143. Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, [Lee SH](#), Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. **J Clin Oncol.** 2020 Oct 7;JCO2001888. doi: 10.1200/JCO.20.01888. Epub ahead of print. PMID: 33026938.

144. Lee J, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? **J Thorac Dis.** 2020 Jul;12(7):3796-3803. doi: 10.21037/jtd.2019.08.29. PMID: 32802459; PMCID: PMC7399433.

145. Kim HK, Joung JG, Choi YL, [Lee SH](#), Park BJ, Choi YS, Ryu D, Nam JY, Lee MS, Park WY, Hwang S, Cha H, Kim HS, Lee S, Jung Y, Lee JE, Doh J, Paik S, Kang JH, Lee J, Kim J. Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma. **iScience.** 2020 Aug 21;23(8):101386. doi: 10.1016/j.isci.2020.101386. Epub 2020 Jul 18. PMID: 32795913; PMCID: PMC7426575.

146. Kim G, Kim J, Cha H, Park WY, Ahn JS, Ahn MJ, Park K, Park YJ, Choi JY, Lee KH, [Lee SH](#), Moon SH. Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. **Sci Rep.** 2020 Aug 6;10(1):13231. doi: 10.1038/s41598-020-70168-x. PMID: 32764738; PMCID: PMC7411040. [[corresponding author](#)]

147. Jung HY, Kim TH, Lee JE, Kim HK, Cho JH, Choi YS, Shin S, [Lee SH](#), Rhee H, Lee HK, Choi HJ, Jang HY, Lee S, Kang JH, Choi YA, Lee S, Lee J, Choi Y, Kim J. PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications. **J Transl Med**. 2020 Aug 6;18(1):307. doi: 10.1186/s12967-020-02473-y. PMID: 32762722; PMCID: PMC7409653.

148. Kim H, Kwon M, Kim B, Jung HA, Sun JM, [Lee SH](#), Park K, Ahn MJ. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. **BMC Cancer**. 2020 Aug 5;20(1):727. doi: 10.1186/s12885-020-07214-4. PMID: 32758163; PMCID: PMC7405432.

149. Lee J, Park S, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Evaluating entrectinib as a treatment option for non-small cell lung cancer. **Expert Opin Pharmacother**. 2020 Jul 31:1-8. doi: 10.1080/14656566.2020.1798932. Epub ahead of print. PMID: 32736487.

150. Lee J, La Choi Y, Han J, Park S, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status. **J Thorac Oncol**. 2020 Jul 8:S1556-0864(20)30505-0. doi: 10.1016/j.jtho.2020.06.018. Epub ahead of print. PMID: 32652216.

151. Park S, Ku BM, Jung HA, Sun JM, Ahn JS, [Lee SH](#), Park K, Ahn MJ. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation. **Cancer Res Treat**. 2020 Jun 22. doi: 10.4143/crt.2020.278. Epub ahead of print. PMID: 32599977.

152. Park S, Shim J, Mortimer PGS, Smith SA, Godin RE, Hollingsworth SJ, Kim HJ, Jung HA, Sun JM, Park WY, Ahn JS, Ahn MJ, [Lee SH](#), Park K. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. **Cancer**. 2020 Jun 25. doi: 10.1002/cncr.33048. Epub ahead of print. PMID: 32584426. [corresponding author]

153. Jung HA, Sun JM, [Lee SH](#), Ahn JS, Ahn MJ, Park K. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care; UNIVERSE-ROOT study). **Lung Cancer**. 2020 May 31;146:112-119. doi: 10.1016/j.lungcan.2020.05.033. Epub ahead of print. PMID: 32526601.

154. Jang JH, Kim Y, Park S, Kim K, Kim SJ, Kim WS, Jung CW, Lee J, [Lee SH](#). Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot

clinical trial in South Korea. **PLoS Med.** 2020 Jun 8;17(6):e1003091. doi: 10.1371/journal.pmed.1003091. PMID: 32511251; PMCID: PMC7279571.

155. Koh J, Kim Y, Lee KY, Hur JY, Kim MS, Kim B, Cho HJ, Lee YC, Bae YH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. MDSC subtypes and CD39 expression on CD8⁺ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. **Eur J Immunol.** 2020 Jun 8. doi: 10.1002/eji.202048534. Epub ahead of print. PMID: 32510574.

156. Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Pyo H, Ahn YC, Park K. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. **Lung Cancer.** 2020 May 31;146:23-29. doi: 10.1016/j.lungcan.2020.05.035. Epub ahead of print. PMID: 32505077.

157. Kim SK, Park JE, Kim KH, Cho JM, Moon J, Yoon WS, Kim SH, Kim YI, Kim YZ, Kim HS, Dho YS, Park JS, Yoon HI, Seo Y, Sung KS, Song JH, Wee CW, Lee SH, Lim DH, Im JH, Chang JH, Han MH, Hong JB, Hwang K, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group. A National Consensus Survey for Current Practice in Brain Tumor Management III: Brain Metastasis and Primary Central Nervous System Lymphoma. **Brain Tumor Res Treat.** 2020 Apr;8(1):20-28. doi: 10.14791/btrt.2020.8.e7. PMID: 32390350; PMCID: PMC7221464.

158. Kim SK, Yoon HI, Yoon WS, Cho JM, Moon J, Kim KH, Kim SH, Kim YI, Kim YZ, Kim HS, Dho YS, Park JS, Park JE, Seo Y, Sung KS, Song JH, Wee CW, Lee SH, Lim DH, Im JH, Chang JH, Han MH, Hong JB, Hwang K, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group. A National Consensus Survey for Current Practice in Brain Tumor Management II: Diffuse Midline Glioma and Meningioma. **Brain Tumor Res Treat.** 2020 Apr;8(1):11-19. doi: 10.14791/btrt.2020.8.e6. PMID: 32390349; PMCID: PMC7221470.

159. Kim SK, Moon J, Cho JM, Kim KH, Kim SH, Kim YI, Kim YZ, Kim HS, Dho YS, Park JS, Park JE, Seo Y, Sung KS, Song JH, Wee CW, Yoon WS, Yoon HI, Lee SH, Lim DH, Im JH, Chang JH, Han MH, Hong JB, Hwang K, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group. A National Consensus Survey for Current Practice in Brain Tumor Management I: Antiepileptic Drug and Steroid Usage. **Brain Tumor Res Treat.** 2020 Apr;8(1):1-10. doi: 10.14791/btrt.2020.8.e5. PMID: 32390348; PMCID: PMC7221462.

160. Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, Choi S, Choi YL, Joung JG, Park WY, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Lee HO. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. **Nat Commun.** 2020 May 8;11(1):2285. doi: 10.1038/s41467-020-16164-1. PMID: 32385277; PMCID: PMC7210975.

161. Lee J, Choi Y, Jung HA, [Lee SH](#), Ahn JS, Ahn MJ, Park K, Sun JM. Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. **Eur J Cancer**. 2020 Jun;132:150-158. doi: 10.1016/j.ejca.2020.03.029. Epub 2020 May 1. PMID: 32371248.

162. Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With *MET* Exon 14 Skipping. **In Vivo**. 2020 May-Jun;34(3):1399-1406. doi: 10.21873/invivo.11920. PMID: 32354937; PMCID: PMC7279794.

163. Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, [Lee SH](#). HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. **Ann Oncol**. 2020 Jul;31(7):902-911. doi: 10.1016/j.annonc.2020.04.004. Epub 2020 Apr 19. PMID: 32320754. [corresponding author]

164. Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn JS, Ahn MJ, Park K, [Lee SH](#). Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. **Cancer**. 2020 Mar 10. doi: 10.1002/cncr.32809. [Epub ahead of print] PubMed PMID: 32154925. [corresponding author]

165. Lee J, Ku BM, Shim JH, La Choi Y, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. **Jpn J Clin Oncol**. 2020 Feb 21. pii: hyaa019. doi: 10.1093/jjco/hyaa019. [Epub ahead of print] PubMed PMID: 32083304.

166. Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. **Oncoimmunology**. 2020 Feb 2;9(1):1722023. doi: 10.1080/2162402X.2020.1722023. eCollection 2020. PubMed PMID: 32076579; PubMed Central PMCID: PMC6999841.

167. Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, Ahn MJ, Park K, [Lee SH](#), Choi JK. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. **Nat Commun**. 2020 Feb 19;11(1):951. doi: 10.1038/s41467-020-14562-z. PubMed PMID: 32075964; PubMed Central PMCID: PMC7031381. [corresponding author]

168. Im Y, Lee J, Kim SJ, Koh WJ, Jhun BW, [Lee SH](#). Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. **Respir Med**. 2020 Jan;161:105853. doi: 10.1016/j.rmed.2019.105853. Epub 2019 Dec 14. PubMed PMID: 32056727. [corresponding author]

169. Byeon S, Cho JH, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. **Cancer Med**. 2020 Apr;9(7):2352-2362. doi: 10.1002/cam4.2868. Epub 2020 Feb 6. PubMed PMID: 32027780; PubMed Central PMCID: PMC7131857.

170. Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, [Lee SH](#), Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG. New Approaches to SCLC Therapy: From the Laboratory to the Clinic. **J Thorac Oncol**. 2020 Apr;15(4):520-540. doi: 10.1016/j.jtho.2020.01.016. Epub 2020 Feb 1. Review. PubMed PMID: 32018053.

171. Shin E, Lim DH, Han J, Nam DH, Park K, Ahn MJ, Kang WK, Lee J, Ahn JS, [Lee SH](#), Sun JM, Jung HA, Chung TY. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. **BMC Ophthalmol**. 2020 Jan 9;20(1):19. doi: 10.1186/s12886-019-1285-9. PubMed PMID: 31918686; PubMed Central PMCID: PMC6953164.

172. Shin HT, Kim NKD, Yun JW, Lee B, Kyung S, Lee KW, Ryu D, Kim J, Bae JS, Park D, Choi YL, [Lee SH](#), Ahn MJ, Park K, Park WY. Junction Location Identifier (JuLI): Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology. **J Mol Diagn**. 2020 Mar;22(3):304-318. doi: 10.1016/j.jmoldx.2019.10.015. Epub 2019 Dec 25. PubMed PMID: 31881333.

173. Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, [Lee SH](#). Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. **Clin Lung Cancer**. 2019 Nov 21. pii: S1525-7304(19)30323-7. doi: 10.1016/j.clcc.2019.11.006. [Epub ahead of print] PubMed PMID: 31839532. [corresponding author]

174. Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). **J Clin Oncol**. 2019 Dec 11;JCO1900931. doi: 10.1200/JCO.19.00931. [Epub ahead of print] PubMed PMID: 31825714.

175. Park S, [Lee SH](#), Park K. In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing. **J Thorac Oncol**. 2019 Dec;14(12):e279-e280. doi: 10.1016/j.jtho.2019.10.010. PubMed PMID: 31757381. [first author]

176. Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, [Lee SH](#), Choi JK. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. **Nat Commun**. 2019 Sep 19;10(1):4278. doi: 10.1038/s41467-019-12159-9. PubMed PMID: 31537801; PubMed Central PMCID: PMC6753140. [corresponding author]

177. Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, [Lee SH](#). Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. **Eur J Cancer**. 2019 Sep 4;120:65-74. doi: 10.1016/j.ejca.2019.08.001. [Epub ahead of print] PubMed PMID: 31493723. [corresponding author]

178. Phi JH, Sun CH, [Lee SH](#), Lee S, Park I, Choi SA, Park SH, Lee JY, Wang KC, Kim SK, Yun H, Park CK. NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors. **BMC Cancer**. 2019 Aug 28;19(1):848. doi: 10.1186/s12885-019-6044-z. PubMed PMID: 31462227. [first author]

179. Lee K, Jung HA, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. **Cancer Res Treat**. 2019 Jul 26. doi: 10.4143/crt.2019.186. [Epub ahead of print] PubMed PMID: 31345011.

180. Park S, Shim JH, Lee B, Cho I, Park WY, Kim Y, [Lee SH](#), Choi Y, Han J, Ahn JS, Ahn MJ, Park K, Sun JM. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. **Lung Cancer**. 2019 Aug;134:7-15. doi: 10.1016/j.lungcan.2019.05.024. Epub 2019 May 24. PubMed PMID: 31319998.

181. Kim Y, Kim CH, Lee HY, [Lee SH](#), Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. **J Thorac Oncol**. 2019 Jun 10. pii: S1556-

0864(19)30454-X. doi: 10.1016/j.jtho.2019.05.033. [Epub ahead of print] PubMed PMID: 31195179. [first author]

182. Park S, Lee H, Lee B, Lee SH, Sun JM, Park WY, Ahn JS, Ahn MJ, Park K. DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer. **J Thorac Oncol**. 2019 May 21. pii: S1556-0864(19)30381-8. doi: 10.1016/j.jtho.2019.05.014. [Epub ahead of print] PubMed PMID: 31125737.

183. Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. **Invest New Drugs**. 2019 May 24. doi: 10.1007/s10637-019-00795-3. [Epub ahead of print] PubMed PMID: 31124056.

184. Park S, Joung JG, Min YW, Nam JY, Ryu D, Oh D, Park WY, Lee SH, Choi Y, Ahn JS, Ahn MJ, Park K, Sun JM. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. **J Immunother Cancer**. 2019 May 16;7(1):128. doi: 10.1186/s40425-019-0609-x. PubMed PMID: 31097034.

185. Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. **Lancet Respir Med**. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10. PubMed PMID: 30981696.

186. Cho WK, Oh D, Kim HK, Ahn YC, Noh JM, Shim YM, Zo JI, Choi YS, Sun JM, Lee SH, Ahn MJ, Park K, Nam H. Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery. **Radiother Oncol**. 2019 Apr;133:87-92. doi: 10.1016/j.radonc.2019.01.005. Epub 2019 Jan 21. PubMed PMID: 30935586.

187. Cho JH, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. **J Cancer Res Clin Oncol**. 2019 May;145(5):1341-1349. doi: 10.1007/s00432-019-02889-0. Epub 2019 Mar 21. PubMed PMID: 30900155.

188. Lee K, Kim Y, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Choi YL, Sun JM. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients

with lung cancer. **Lung Cancer**. 2019 Apr;130:87-92. doi: 10.1016/j.lungcan.2019.01.012. Epub 2019 Jan 28. PubMed PMID: 30885357.

189. Shin SH, Park HY, Im Y, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee HY, [Lee SH](#). Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease. **Int J Cancer**. 2019 Feb 26. doi: 10.1002/ijc.32235. [Epub ahead of print] PubMed PMID: 30807641. [corresponding author]

190. Keam B, Lee KW, [Lee SH](#), Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. **Oncologist**. 2019 Feb 22. pii: theoncologist.2019-0070. doi: 10.1634/theoncologist.2019-0070. [Epub ahead of print] PubMed PMID: 30796155. [corresponding author]

191. Lee J, Sun JM, [Lee SH](#), Ahn JS, Park K, Choi Y, Ahn MJ. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. **Clin Lung Cancer**. 2018 Dec 31. pii: S1525-7304(18)30357-7. doi: 10.1016/j.clcc.2018.12.020. [Epub ahead of print] PubMed PMID: 30683630.

192. Kim KH, Cho J, Ku BM, Koh J, Sun JM, [Lee SH](#), Ahn JS, Cheon J, Min YJ, Park SH, Park K, Ahn MJ, Shin EC. The First-week Proliferative Response of Peripheral Blood PD-1(+)/CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. **Clin Cancer Res**. 2019 Jan 15. doi: 10.1158/1078-0432.CCR-18-1449. [Epub ahead of print] PubMed PMID: 30647082.

193. Kim H, Oh D, Ahn YC, Park K, Ahn MJ, [Lee SH](#), Sun JM, Shim YM, Zo JI, Choi YS, Kim HK, Cho JH. Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. **Radiat Oncol**. 2018 Dec 14;13(1):245. doi: 10.1186/s13014-018-1196-6. PubMed PMID: 30547802; PubMed Central PMCID: PMC6295084.

194. Kim Y, Lee B, Shim JH, [Lee SH](#), Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer. **J Thorac Oncol**. 2018 Oct 31. pii: S1556-0864(18)33383-5. doi: 10.1016/j.jtho.2018.10.150. [Epub ahead of print] PubMed PMID: 30391576. [corresponding author]

195. Lim SW, Park S, Kim Y, Cho JH, Park SE, Lee H, Kim HK, Kim SM, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Continuation of gefitinib beyond progression in patients with EGFR

mutation-positive non-small-cell lung cancer: A phase II single-arm trial. **Lung Cancer**. 2018 Oct;124:293-297. doi: 10.1016/j.lungcan.2018.08.003. Epub 2018 Aug 3. PubMed PMID: 30268476.

196. Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. **Cancer Res Treat**. 2018 Sep 3. doi: 10.4143/crt.2018.324. [Epub ahead of print] PubMed PMID: 30177585.

197. Moon SH, Kim J, Joung JG, Cha H, Park WY, Ahn JS, Ahn MJ, Park K, Choi JY, Lee KH, Kim BT, [Lee SH](#). Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. **Eur J Nucl Med Mol Imaging**. 2018 Aug 25. doi: 10.1007/s00259-018-4138-5. [Epub ahead of print] PubMed PMID: 30145701. [corresponding author]

198. Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. **Cancer Res Treat**. 2018 Jul 23. doi: 10.4143/crt.2018.151. [Epub ahead of print] PubMed PMID: 30049203.

199. Lee J, Jung HA, Kim Y, Choi S, Han J, Choi YL, [Lee SH](#), Ahn JS, Park K, Sun JM. Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. **Lung Cancer**. 2018 Aug;122:160-164. doi: 10.1016/j.lungcan.2018.06.009. Epub 2018 Jun 9. PubMed PMID: 30032825.

200. Pyo H, [Lee SH](#), Kim J. The more and the heavier may not always be an answer. **J Thorac Dis**. 2018 Jun;10(Suppl 17):S1953-S1955. doi: 10.21037/jtd.2018.04.127. PubMed PMID: 30023089; PubMed Central PMCID: PMC6036047. (editorial)

201. Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW, Ahn YC, Pyo H, Choi YL, Han J, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. EGFR Mutation is Associated with Short Progression Free Survival in Patients with Stage III Non-Squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. **Cancer Res Treat**. 2018 Jun 18. doi: 10.4143/crt.2018.125. [Epub ahead of print] PubMed PMID: 29914238.

202. Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor:

An Open-Label Phase II Trial. **J Clin Oncol**. 2018 Jun 15;JCO2017773184. doi: 10.1200/JCO.2017.77.3184. [Epub ahead of print] PubMed PMID: 29906252.

203. Park I, [Lee SH](#), Lee JL. A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus. **Clin Genitourin Cancer**. 2018 May 23. pii: S1558-7673(18)30149-6. doi: 10.1016/j.clgc.2018.05.011. [Epub ahead of print] PubMed PMID: 29903415.

204. Kim Y, [Lee SH](#), Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. **Cancer Res Treat**. 2018 Jun 13. doi: 10.4143/crt.2018.117. [Epub ahead of print] PubMed PMID: 29898592.

205. Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, [Lee SH](#), Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. **J Thorac Oncol**. 2018 Jun 5. pii: S1556-0864(18)30673-7. doi: 10.1016/j.jtho.2018.05.026. [Epub ahead of print] PubMed PMID: 29883837.

206. Lee J, Shim JH, Park WY, Kim HK, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. **Cancer Res Treat**. 2018 May 23. doi: 10.4143/crt.2018.138. [Epub ahead of print] PubMed PMID: 29807405.

207. Noh KW, Sohn I, Song JY, Shin HT, Kim YJ, Jung K, Sung M, Kim M, An S, Han J, [Lee SH](#), Lee MS, Choi YL. Integrin $\beta 3$ Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC. **Clin Cancer Res**. 2018 May 18. doi: 10.1158/1078-0432.CCR-17-3492. [Epub ahead of print] PubMed PMID: 29776956.

208. Lee H, Lee HY, Sun JM, [Lee SH](#), Kim Y, Park SE, Ahn JS, Park K, Ahn MJ. Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. **J Thorac Oncol**. 2018 Aug;13(8):1106-1112. doi: 10.1016/j.jtho.2018.04.038. PubMed PMID: 29775809.

209. [Lee SH](#), Lee B, Shim JH, Lee KW, Yun JW, Kim SY, Kim TY, Kim YH, Ko YH, Chung HC, Yu CS, Lee J, Rha SY, Kim TW, Jung KH, Im SA, Moon HG, Cho S, Kang JH, Kim J, Kim SK, Ryu HS, Ha SY, Kim JI, Chung YJ, Kim C, Kim HL, Park WY, Noh DY, Park K. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer

Patients. **Cancer Res Treat.** 2018 Apr 23. doi: 10.4143/crt.2018.132. [Epub ahead of print] PubMed PMID: 29690749. [first author]

210. Ku BM, Choi MK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. **PLoS One.** 2018 Apr 11;13(4):e0194730. doi: 10.1371/journal.pone.0194730. eCollection 2018. PubMed PMID: 29641535.

211. Ku BM, Heo MH, Kim JH, Cho BC, Cho EK, Min YJ, Lee KH, Sun JM, Lee SH, Ahn JS, Park K, Kim TJ, Lee HY, Kim H, Lee KJ, Ahn MJ. Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). **J Pathol Transl Med.** 2018 Mar 26. doi: 10.4132/jptm.2018.03.12. [Epub ahead of print] PubMed PMID: 29575851.

212. Park BJ, Cho JH, Lee JH, Shin S, Kim HK, Choi YS, Zo JI, Shim YM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K, Kim J. Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. **Lung Cancer.** 2018 Mar;117:7-13. doi: 10.1016/j.lungcan.2018.01.004. Epub 2018 Jan 6. PubMed PMID: 29496256.

213. Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. **J Thorac Oncol.** 2018 Mar;13(3):e34-e36. doi: 10.1016/j.jtho.2017.10.007. PubMed PMID: 29472055. (case report)

214. Jeon YJ, Choi YS, Lee KJ, Lee SH, Pyo H, Choi JY. Outcomes of Pulmonary Resection and Mediastinal Node Dissection by Video-Assisted Thoracoscopic Surgery Following Neoadjuvant Chemoradiation Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer. **Korean J Thorac Cardiovasc Surg.** 2018 Feb;51(1):29-34. doi: 10.5090/kjtcs.2018.51.1.29. Epub 2018 Feb 5. PubMed PMID: 29430426; PubMed Central PMCID: PMC5796615.

215. Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, Kim DW, Heo DS. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. **PLoS One.** 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018. PubMed PMID: 29385152; PubMed Central PMCID: PMC5791940. [corresponding author]

216. Sun JM, Lee KH, Kim BS, Kim HG, Min YJ, Yi SY, Yun HJ, Jung SH, Lee SH, Ahn JS, Park K, Ahn MJ. Pazopanib maintenance after first-line etoposide and platinum chemotherapy

in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). **Br J Cancer**. 2018 Jan 30. doi: 10.1038/bjc.2017.465. [Epub ahead of print] PubMed PMID: 29381690.

217. Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, Kim SW, Lee DH, Park K, Ahn MJ, Chung JH, Shong YK, Kim WG, Kim TH. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. **Oncoimmunology**. 2017 Sep 21;7(1):e1375642. doi: 10.1080/2162402X.2017.1375642. eCollection 2017. PubMed PMID: 29296533; PubMed Central PMCID: PMC5739550.

218. Shin HT, Choi YL, Yun JW, Kim NKD, Kim SY, Jeon HJ, Nam JY, Lee C, Ryu D, Kim SC, Park K, Lee E, Bae JS, Son DS, Joung JG, Lee J, Kim ST, Ahn MJ, Lee SH, Ahn JS, Lee WY, Oh BY, Park YH, Lee JE, Lee KH, Kim HC, Kim KM, Im YH, Park K, Park PJ, Park WY. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. **Nat Commun**. 2017 Nov 9;8(1):1377. doi: 10.1038/s41467-017-01470-y. PubMed PMID: 29123093; PubMed Central PMCID: PMC5680209.

219. Cho JH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. **J Thorac Oncol**. 2017 Nov 2. pii: S1556-0864(17)32858-7. doi: 10.1016/j.jtho.2017.10.014. [Epub ahead of print] PubMed PMID: 29102694.

220. Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. **J Thorac Oncol**. 2018 Jan;13(1):106-111. doi: 10.1016/j.jtho.2017.10.011. Epub 2017 Oct 31. PubMed PMID: 29101058.

221. Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. **Oncotarget**. 2017 Jun 28;8(40):67526-67537. doi: 10.18632/oncotarget.18728. eCollection 2017 Sep 15. PubMed PMID: 28978051; PubMed Central PMCID: PMC5620191.

222. Sun JM, Noh JM, Oh D, Kim HK, Lee SH, Choi YS, Pyo H, Ahn JS, Jung SH, Ahn YC, Kim J, Ahn MJ, Zo JI, Shim YM, Park K. Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. **J Thorac Oncol**. 2017 Dec;12(12):1806-1813. doi: 10.1016/j.jtho.2017.09.1954. Epub 2017 Sep 28. PubMed PMID: 28962948.

223. Kim S, Kim JE, Kim YH, Hwang T, Kim SK, Xu WJ, Shin JY, Kim JI, Choi H, Kim HC, Cho HR, Choi A, Chowdhury T, Seo Y, Dho YS, Kim JW, Kim DG, Park SH, Kim H, Choi SH, Park S, [Lee SH](#), Park CK. Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma. **Sci Rep**. 2017 Sep 22;7(1):12221. doi: 10.1038/s41598-017-12557-3. PubMed PMID: 28939850; PubMed Central PMCID: PMC5610329.

224. Reynolds KL, Bedard PL, [Lee SH](#), Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. **BMC Cancer**. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6. PubMed PMID: 28899363; PubMed Central PMCID: PMC5596462.

225. Ku BM, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. **Expert Rev Mol Diagn**. 2017 Oct;17(10):933-942. doi: 10.1080/14737159.2017.1372196. Epub 2017 Aug 30. PubMed PMID: 28838271.

226. Hsu C, [Lee SH](#), Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. **J Clin Oncol**. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24. PubMed PMID: 28837405.

227. Noh KW, Lee MS, Lee SE, Song JY, Shin HT, Kim YJ, Oh DY, Jung K, Sung M, Kim M, An S, Han J, Shim YM, Zo JI, Kim J, Park WY, [Lee SH](#), Choi YL. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. **J Pathol**. 2017 Nov;243(3):307-319. doi: 10.1002/path.4950. Epub 2017 Sep 28. PubMed PMID: 28741662. [corresponding author]

228. Kim HK, Heo MH, Lee HS, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. **Cancer Chemother Pharmacol**. 2017 Sep;80(3):591-598. doi: 10.1007/s00280-017-3396-4. Epub 2017 Jul 21. PubMed PMID: 28733892.

229. Jung KS, Lee SJ, Park SH, Lee JL, [Lee SH](#), Lim JY, Kang JH, Lee S, Rha SY, Lee KH, Kim HY, Lim HY. Pazopanib for the Treatment of Non-Clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. **Cancer Res Treat.** 2017 May 22. doi: 10.4143/crt.2016.584. [Epub ahead of print] PubMed PMID: 28546525.

230. Lee Y, Park S, [Lee SH](#), Lee H. Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma. **BMC Cancer.** 2017 May 15;17(1):330. doi: 10.1186/s12885-017-3282-9. PubMed PMID: 28506304; PubMed Central PMCID: PMC5432996. [corresponding author]

231. Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, [Lee SH](#), Park K, Ku JL, Jeon YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. **J Clin Oncol.** 2017 May 12;JCO2016719096. doi: 10.1200/JCO.2016.71.9096. [Epub ahead of print] PubMed PMID: 28498782.

232. Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Sun JM, [Lee SH](#), Ahn MJ, Park K, Kim DH, Lee S, Park W, Kim KM. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. **Oncotarget.** 2017 Apr 18. doi: 10.18632/oncotarget.17199. [Epub ahead of print] PubMed PMID: 28477007.

233. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, [Lee SH](#), Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. **Oncotarget.** 2017 Apr 13. doi: 10.18632/oncotarget.17102. [Epub ahead of print] PubMed PMID: 28467813.

234. Park S, Kim JY, [Lee SH](#), Suh B, Keam B, Kim TM, Kim DW, Heo DS. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. **Korean J Intern Med.** 2017 Apr 14. doi: 10.3904/kjim.2015.299. [Epub ahead of print] PubMed PMID: 28407465. [corresponding author]

235. Lee S, Lee J, Sim SH, Lee Y, Moon KC, Lee C, Park WY, Kim NK, [Lee SH](#), Lee H. Comprehensive somatic genome alterations of urachal carcinoma. **J Med Genet.** 2017 Mar 27. pii: jmedgenet-2016-104390. doi: 10.1136/jmedgenet-2016-104390. [Epub ahead of print] PubMed PMID: 28348108. [corresponding author]

236. Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K. EGFR TKI combination with immunotherapy in non-small cell lung cancer. **Expert Opin Drug Saf.** 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8. Review. PubMed PMID: 28271729.

237. Lee HY, [Lee SH](#), Won JK, Lee DS, Kwon NJ, Choi SM, Lee J, Lee CH, Lee SM, Yim JJ, Yoo CG, Kim YW, Han SK, Park YS. Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. **J Korean Med Sci.** 2017 Mar;32(3):415-420. doi: 10.3346/jkms.2017.32.3.415. PubMed PMID: 28145643; PubMed Central PMCID: PMC5290099.

238. [Lee SH](#), [Lee JK](#). Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC. **Lancet Respir Med.** 2017 Feb;5(2):e10. doi: 10.1016/S2213-2600(17)30010-3. PubMed PMID: 28145234. [corresponding author]

239. Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Osimertinib for the treatment of non-small cell lung cancer. **Expert Opin Pharmacother.** 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283. PubMed PMID: 28116908.

240. Kim Y, Lee SJ, Lee JY, [Lee SH](#), Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, Kim HR, Lee KE, Choi MY, Lee KH, Ahn MJ. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). **Cancer.** 2017 Jan 19. doi: 10.1002/cncr.30537. [Epub ahead of print] PubMed PMID: 28102887.

241. Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, [Lee SH](#), Park K, Oh YL, Hong M, Jeong HS, Son YI, Baek CH, Ahn MJ. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. **Cancer Res Treat.** 2016 Dec 26. doi: 10.4143/crt.2016.424. [Epub ahead of print] PubMed PMID: 28052655.

242. Lim SH, Kim SY, Kim K, Jang H, Ahn S, Kim KM, Kim NK, Park W, Lee SJ, Kim ST, Park SH, Park JO, Park YS, [Lee SH](#), Lim HY, Park K, Kang WK, Lee J. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. **Oncotarget.** 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. PubMed PMID: 27906677.

243. Ahn MJ, Sun JM, [Lee SH](#), Ahn JS, Park K. Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision. **J Thorac Oncol.** 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130. PubMed PMID: 27866634.

244. [Park S](#), [Park S](#), [Lee SH](#), Suh B, Keam B, Kim TM, Kim DW, Kim YW, Heo DS. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell

lung cancer with activating epidermal growth factor receptor mutations. **Korean J Intern Med.** 2016 Nov;31(6):1140-1149. PubMed PMID: 27017943; PubMed Central PMCID: PMC5094922. [corresponding author]

245. [Lee SH](#), Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K. Vandetanib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring RET Rearrangement: A Phase II Clinical Trial. **Ann Oncol.** 2016 Nov 1. pii: mdw559. [Epub ahead of print] PubMed PMID: 27803005. [corresponding author]

246. Cho JK, Hyun SH, Choi JY, Choi N, Kim MJ, [Lee SH](#), Baek KH, Jeong HS. Prognostic significance of clinical and (18) F-FDG PET/CT parameters for post-distant metastasis survival in head and neck squamous cell carcinoma patients. **J Surg Oncol.** 2016 Dec;114(7):888-894. doi: 10.1002/jso.24412. PubMed PMID: 27546387.

247. Kang RY, Yoo KS, Han HJ, Lee JY, [Lee SH](#), Kim DW, Lee YJ. Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. **Support Care Cancer.** 2017 Feb;25(2):429-437. doi: 10.1007/s00520-016-3420-y. PubMed PMID: 27687722.

248. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtneess B, [Lee SH](#), Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. **J Clin Oncol.** 2016 Sep 19. pii: JCO681478. [Epub ahead of print] PubMed PMID: 27646946.

249. Kim MJ, Park SH, Lee JL, [Lee SH](#), Lee SJ, Lim HY. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. **BMC Urol.** 2016 Aug 2;16(1):46. doi: 10.1186/s12894-016-0163-5. PubMed PMID: 27484998; PubMed Central PMCID: PMC4970295.

250. Kim SK, Kim TM, Lee ST, Lee SH, Heo DS, Kim IH, Kim DG, Jung HW, Choi SH, [Lee SH](#), Park CK. The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. **J Clin Neurosci.** 2016 Jul 27. pii: S0967-5868(16)30442-8. doi: 10.1016/j.jocn.2016.06.014. [Epub ahead of print] PubMed PMID: 27475318.

251. Byeon S, Ham JS, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer

and brain metastasis. **Med Oncol**. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22. PubMed PMID: 27447711; PubMed Central PMCID: PMC4958121.

252. Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH, Cho YH, Yoon SM, Chang JH, Kang SG, Kim EH, Suh CO, Jung TY, Lee KH, Kim CY, Kim IA, Hong CK, Yoo H, Kim JH, Kang SH, Kang MK, Kim EY, Kim SH, Chung DS, Hwang SC, Song JH, Cho SJ, Lee SI, Lee YS, Ahn KJ, Kim SH, Lim DH, Gwak HS, Lee SH, Hong YK. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. **Cancer Res Treat**. 2016 Jun 27. doi: 10.4143/crt.2015.473. [Epub ahead of print] PubMed PMID: 27384161. [corresponding author]

253. Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, Cho BC, Ahn MJ. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. **Cancer**. 2016 Jun 17. doi: 10.1002/cncr.30135. [Epub ahead of print] PubMed PMID: 27315356.

254. Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. **Cancer Res Treat**. 2016 May 18. doi: 10.4143/crt.2015.466. [Epub ahead of print] PubMed PMID: 27188199. [corresponding author]

255. Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ, Park W. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. **J Pathol Transl Med**. 2016 May 10. doi: 10.4132/jptm.2016.04.19. [Epub ahead of print] PubMed PMID: 27160687.

256. Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. **Lung Cancer**. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26. PubMed PMID: 27133749.

257. Park S, Park S, Lee SH, Suh B, Ock CY, Keam B, Kim TM, Kim DW, Kim YW, Heo DS. Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. **Cancer Biomark**. 2016 Mar 4;16(3):425-33. doi: 10.3233/CBM-160581. PubMed PMID: 27062699. [corresponding author]

258. Ku BM, Bae YH, Koh J, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. **Invest New Drugs**. 2016 Apr 5. [Epub ahead of print] PubMed PMID: 27044261.

259. Sim SH, Beom SH, Ahn YO, Keam B, Kim TM, [Lee SH](#), Kim DW, Heo DS. Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. **Thorac Cancer**. 2016 Mar;7(2):161-6. doi: 10.1111/1759-7714.12304. Epub 2015 Aug 28. PubMed PMID: 27042217; PubMed Central PMCID: PMC4773306.

260. Lee B, Lee T, [Lee SH](#), Choi YL, Han J. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. **Oncotarget**. 2016 Mar 14. doi: 10.18632/oncotarget.8074. [Epub ahead of print] PubMed PMID: 26992209.

261. Ock CY, Keam B, Kim TM, Han DH, Won TB, [Lee SH](#), Hah JH, Kwon TK, Kim DW, Kim DY, Rhee CS, Wu HG, Sung MW, Heo DS. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. **Korean J Intern Med**. 2016 Mar 15. doi: 10.3904/kjim.2015.020. [Epub ahead of print] PubMed PMID: 26976150.

262. Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, [Lee SH](#), Kim JI. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. **BMC Cancer**. 2016 Feb 29;16(1):170. doi: 10.1186/s12885-016-2209-1. PubMed PMID: 26925973; PubMed Central PMCID: PMC4772349. [corresponding author]

263. Ku BM, Yi SY, Koh J, Bae YH, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. **Oncotarget**. 2016 Feb 21. doi: 10.18632/oncotarget.7543. [Epub ahead of print] PubMed PMID: 26909611.

264. Heo H, Kim S, Lee HH, Cho HR, Xu WJ, [Lee SH](#), Park CK, Park S, Choi SH, Kim H. On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. **PLoS One**. 2016 Jan 28;11(1):e0147794. doi: 10.1371/journal.pone.0147794. eCollection 2016. PubMed PMID: 26820720; PubMed Central PMCID: PMC4731570.

265. Lim SH, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Pembrolizumab for the treatment of non-small cell lung cancer. **Expert Opin Biol Ther.** 2016 Jan 22. [Epub ahead of print] PubMed PMID: 26800463. (review)

266. Yang Y, Lim O, Kim TM, Ahn YO, Choi HN, Chung H, Min B, Her JH, Cho SY, Keam B, [Lee SH](#), Kim DW, Hwang YK, Heo DS. Phase I study of random, healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. **Cancer Immunol Res.** 2016 Jan 19. pii: canimm.0118.2015. [Epub ahead of print] PubMed PMID: 26787822.

267. Ham JS, Kim S, Kim HK, Byeon S, Sun JM, [Lee SH](#), Ahn JS, Park K, Choi YL, Han J, Park W, Ahn MJ. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. **J Thorac Oncol.** 2016 Jan;11(1):e1-4. doi: 10.1016/j.jtho.2015.09.013. PubMed PMID: 26762749. (case report)

268. Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, [Lee SH](#), Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). **Oncotarget.** 2016 Jan 9. doi: 10.18632/oncotarget.6874. [Epub ahead of print] PubMed PMID: 26755650.

269. Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, Kim HS, Sun JM, [Lee SH](#), Ahn JS, Park K, Choi YL, Park W, Ahn MJ. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. **J Thorac Oncol.** 2015 Dec 31. pii: S1556-0864(15)00209-9. doi: 10.1016/j.jtho.2015.12.093. [Epub ahead of print] PubMed PMID: 26749488. (case report)

270. [Lee SH](#), Park K. The MISSION: Impossible? No, the Journey Should Continue with Better Targeting! **J Thorac Oncol.** 2015 Dec;10(12):1667-9. doi: 10.1097/JTO.0000000000000701. PubMed PMID: 26709476. (editorial)

271. Han JJ, Kim DW, Koh J, Keam B, Kim TM, Jeon YK, [Lee SH](#), Chung DH, Heo DS. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. **Clin Lung Cancer.** 2015 Dec 1. pii: S1525-7304(15)00270-3. doi: 10.1016/j.clcc.2015.11.006. [Epub ahead of print] PubMed PMID: 26707383.

272. Lee JY, Sun JM, Oh DR, Lim SH, Goo J, [Lee SH](#), Kim SB, Park KU, Kim HK, Hong DS, Kim JS, Kim SG, Yi SY, Yun HJ, Hyun MS, Kim HJ, Jung SH, Park K, Ahn YC, Ahn MJ. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter

randomized phase II trial (KCSG-HN10-02). **Radiother Oncol.** 2015 Dec 16. pii: S0167-8140(15)00650-7. doi: 10.1016/j.radonc.2015.11.030. [Epub ahead of print] PubMed PMID: 26705681.

273. Ock CY, Son B, Keam B, Lee SY, Moon J, Kwak H, Kim S, Kim TM, Jeon YK, Kwon SK, Hah JH, Lee SH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. **J Cancer Res Clin Oncol.** 2015 Dec 16. [Epub ahead of print] PubMed PMID: 26677030.

274. Lee JY, Sun JM, Lim SH, Kim H, Yoo KH, Jung KS, Song HN, Ku BM, Koh J, Bae YH, Lee SH, Ahn JS, Park K, Ahn MJ. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. **Clin Cancer Res.** 2015 Dec 14. pii: clincanres.1653.2015. [Epub ahead of print] PubMed PMID: 26667485.

275. Lee EK, Choi SH, Yun TJ, Kang KM, Kim TM, Lee SH, Park CK, Park SH, Kim IH. Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging. **Korean J Radiol.** 2015 Nov-Dec;16(6):1341-8. doi: 10.3348/kjr.2015.16.6.1341. Epub 2015 Oct 26. PubMed PMID: 26576125; PubMed Central PMCID: PMC4644757.

276. Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. **Korean J Intern Med.** 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30. PubMed PMID: 26552465; PubMed Central PMCID: PMC4642019.

277. Lee DY, Won JK, Lee SH, Park DJ, Jung KC, Sung MW, Wu HG, Kim KH, Park YJ, Hah JH. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma. **Thyroid.** 2015 Dec 14. [Epub ahead of print] PubMed PMID: 26541309.

278. Park CK, Park I, Lee S, Sun CH, Koh Y, Park SH, Kim JE, Yun H, Lee SH. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. **Oncotarget.** 2015 Dec 22;6(41):43653-66. doi: 10.18632/oncotarget.6189. PubMed PMID: 26524630. [corresponding author]

279. Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in

Patients with Unresectable Thymic Epithelial Tumors. **J Thorac Oncol**. 2015 Oct 16. [Epub ahead of print] PubMed PMID: 26484631.

280. Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK, [Lee SH](#), Chung DH, Heo DS. Mechanisms of Acquired Resistance to AZD9291, a Mutation-Selective, Irreversible EGFR Inhibitor. **J Thorac Oncol**. 2015 Dec;10(12):1736-44. doi: 10.1097/JTO.0000000000000688. PubMed PMID: 26473643.

281. Lee SJ, Sun JM, [Lee SH](#), Ahn JS, Park K, Ahn MJ. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. **Lung Cancer**. 2015 Sep 4. pii: S0169-5002(15)30044-1. doi: 10.1016/j.lungcan.2015.08.020. [Epub ahead of print] PubMed PMID: 26371700.

282. Yoo DH, Song SW, Yun TJ, Kim TM, [Lee SH](#), Kim JH, Sohn CH, Park SH, Park CK, Kim IH, Choi SH. MR Imaging Evaluation of Intracerebral Hemorrhages and T2 Hyperintense White Matter Lesions Appearing after Radiation Therapy in Adult Patients with Primary Brain Tumors. **PLoS One**. 2015 Aug 31;10(8):e0136795. doi: 10.1371/journal.pone.0136795. eCollection 2015. PubMed PMID: 26322780; PubMed Central PMCID: PMC4556481.

283. Koh Y, Park I, Sun CH, Lee S, Yun H, Park CK, Park SH, Park JK, [Lee SH](#). Detection of a Distinctive Genomic Signature in Rhabdoid Glioblastoma, A Rare Disease Entity Identified by Whole Exome Sequencing and Whole Transcriptome Sequencing. **Transl Oncol**. 2015 Aug;8(4):279-287. doi: 10.1016/j.tranon.2015.05.003. PubMed PMID: 26310374. [corresponding author]

284. Lee KW, Koh Y, Kim SB, Shin SW, Kang JH, Wu HG, Sung MW, Keam B, Kim DW, Kim TM, Kim KH, Kwon TK, Hah JH, Kim IA, Ahn SH, Yoon DH, Lee SW, Kim SY, Nam SY, Jung KY, Baek SK, Hong SH, [Lee SH](#), Heo DS. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. **Oncologist**. 2015 Oct;20(10):1119-20. doi: 10.1634/theoncologist.2015-0208. Epub 2015 Aug 24. PubMed PMID: 26304911; PubMed Central PMCID: PMC4591951. [corresponding author]

285. Yoo RE, Choi SH, Kim TM, [Lee SH](#), Park CK, Park SH, Kim IH, Yun TJ, Kim JH, Sohn CH. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. **AJNR Am J Neuroradiol**. 2015 Aug 20. [Epub ahead of print] PubMed PMID: 26294653.

286.Sunwoo L, Choi SH, Yoo RE, Kang KM, Yun TJ, Kim TM, [Lee SH](#), Park CK, Kim JH, Park SW, Sohn CH, Won JK, Park SH, Kim IH. Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. **Neuroradiology**. 2015 Aug 1. [Epub ahead of print] PubMed PMID: 26232204.

287.Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, Kim TM, Heo DS, [Lee SH](#), Moon KC. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. **PLoS One**. 2015 Jul 22;10(7):e0133371. doi: 10.1371/journal.pone.0133371. eCollection 2015. PubMed PMID: 26200905; PubMed Central PMCID: PMC4511592. [corresponding author]

288.Keam B, Lee SJ, Kim TM, Paeng JC, [Lee SH](#), Kim DW, Jeon YK, Chung DH, Kang KW, Chung JK, Heo DS. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. **J Thorac Oncol**. 2015 Aug;10(8):1189-94. doi: 10.1097/JTO.0000000000000569. PubMed PMID: 26200273.

289.Park S, Nam SJ, Keam B, Kim TM, Jeon YK, [Lee SH](#), Hah JH, Kwon TK, Kim DW, Sung MW, Heo DS, Bang YJ. VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma. **Cancer Res Treat**. 2015 Jul 14. doi: 10.4143/crt.2015.093. [Epub ahead of print] PubMed PMID: 26194375.

290.Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, [Lee SH](#), Min HS, Kim YT, Kim DW, Jeon YK, Chung DH. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. **Mod Pathol**. 2015 Jul 17. doi: 10.1038/modpathol.2015.63. [Epub ahead of print] PubMed PMID: 26183759.

291.Jung KY, Kim SM, Yoo WS, Kim BW, Lee YS, Kim KW, Lee KE, Jeong JJ, Nam KH, [Lee SH](#), Hah JH, Chung WY, Yi KH, Park DJ, Youn YK, Sung MW, Cho BY, Park CS, Park YJ, Chang HS. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years. **Clin Endocrinol (Oxf)**. 2015 Jul 14. doi: 10.1111/cen.12852. [Epub ahead of print] PubMed PMID: 26175307.

292.Ock CY, Keam B, Lim Y, Kim TM, [Lee SH](#), Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy:

Single center experience. **Head Neck**. 2014 Oct 17. doi: 10.1002/hed.23891. [Epub ahead of print] PubMed PMID: 26104823.

293. Kim BS, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. **J Neurooncol**. 2015 Aug;124(1):101-10. doi: 10.1007/s11060-015-1808-z. Epub 2015 May 31. PubMed PMID: 26026859.

294. Kim JE, Cho HR, Xu WJ, Kim JY, Kim SK, Kim SK, Park SH, Kim H, Lee SH, Choi SH, Park S, Park CK. Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. **Oncotarget**. 2015 May 10. [Epub ahead of print] PubMed PMID: 26008980.

295. Kim JY, Lee SH, Moon KC, Kwak C, Kim HH, Keam B, Kim TM, Heo DS. The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. **J Urol**. 2015 Oct;194(4):1112-9. doi: 10.1016/j.juro.2015.04.114. Epub 2015 May 18. PubMed PMID: 25997916. [corresponding author]

296. Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, Yun HJ, Lee SH, Yoon DH, Bang YJ. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. **Cancer**. 2015 Apr 22. doi: 10.1002/cncr.29401. [Epub ahead of print] PubMed PMID: 25903089.

297. Ha H, Keam B, Kim TM, Jeon YK, Lee SH, Kim DW, Kim CW, Heo DS. Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. **Cancer Res Treat**. 2015 Apr 9. doi: 10.4143/crt.2014.339. [Epub ahead of print] PubMed PMID: 25865654.

298. Beom SH, Kim DW, Sim SH, Keam B, Park JH, Lee JO, Kim TM, Lee SH, Heo DS. Gefitinib-induced Interstitial Lung Disease in Korean Lung Cancer Patients. **Cancer Res Treat**. 2015 Mar 3. doi: 10.4143/crt.2014.201. [Epub ahead of print] PubMed PMID: 25761482.

299. Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, Heo DS, Yuasa M, Yanagihara Y, Bang YJ. Phase I study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. **Cancer Res Treat**. 2015 Feb 26. doi: 10.4143/crt.2014.249. [Epub ahead of print] PubMed PMID: 25715763.

300. Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell

Lung Cancer. **Clin Cancer Res.** 2015 May 15;21(10):2379-87. doi: 10.1158/1078-0432.CCR-14-1350. Epub 2015 Feb 16. PubMed PMID: 25688157.

301. Choi Y, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. Cancer Treatment Near the End-of-life Becomes More Aggressive: Changes in Trend During 10 Years at a Single Institute. **Cancer Res Treat.** 2015 Feb 16. doi: 10.4143/crt.2014.200. [Epub ahead of print] PubMed PMID: 25687851.

302. Park S, Keam B, Kim SH, Kim KH, Kim YJ, Kim JS, Kim TM, Lee SH, Kim DW, Lee JS, Heo DS. Pemetrexed Singlet versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-Small Cell Lung Cancer Patients with EGFR Mutations. **Cancer Res Treat.** 2015 Feb 16. doi: 10.4143/crt.2014.244. [Epub ahead of print] PubMed PMID: 25687850.

303. Lee YG, Lee E, Kim I, Lee KW, Kim TM, Lee SH, Kim DW, Heo DS. Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. **Cancer Res Treat.** 2015 Jan 2. doi: 10.4143/crt.2014.045. [Epub ahead of print] PubMed PMID: 25672586.

304. Keam B, Kim S, Ahn YO, Kim TM, Lee SH, Kim DW, Heo DS. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. **Anticancer Res.** 2015 Jan;35(1):175-82. PubMed PMID: 25550549.

305. Lee JK, Kim DW, Keam B, Kim TM, Lee SH, Kim YJ, Heo DS. The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. **Cancer Res Treat.** 2015 Apr;47(2):182-8. doi: 10.4143/crt.2013.227. Epub 2014 Sep 12. PubMed PMID: 25544584; PubMed Central PMCID: PMC4398109.

306. Yoo KE, Kang RY, Lee JY, Lee YJ, Suh SY, Kim KS, Kim HS, Lee SH, Lee BK. Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy. **Support Care Cancer.** 2015 Jul;23(7):1969-77. doi: 10.1007/s00520-014-2547-y. Epub 2014 Dec 13. PubMed PMID: 25500718.

307. Myung JK, Cho HJ, Kim H, Park CK, Lee SH, Choi SH, Park P, Yoon JM, Park SH. Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status. **Transl Oncol.** 2014 Dec;7(6):712-9. doi: 10.1016/j.tranon.2014.10.002. PubMed PMID: 25500080; PubMed Central PMCID: PMC4311043.

308. Koh J, Cho H, Kim H, Kim SI, Yun S, Park CK, [Lee SH](#), Choi SH, Park SH. IDH2 mutation in gliomas including novel mutation. **Neuropathology**. 2015 Jun;35(3):236-44. doi: 10.1111/neup.12187. Epub 2014 Dec 12. PubMed PMID: 25495392.

309. Lee DW, Shin DY, Kim JW, Keam B, Kim TM, Kim HJ, Kim DW, Wu HG, Paek SH, Kim YW, Heo DS, Kim DG, [Lee SH](#). Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. **Lung Cancer**. 2014 Dec;86(3):363-8. doi: 10.1016/j.lungcan.2014.10.001. Epub 2014 Oct 13. PubMed PMID: 25453849. [corresponding author]

310. Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, [Lee SH](#), Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. **Clin Cancer Res**. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. PubMed PMID: 25424851.

311. Kim JH, Choi SH, Ryoo I, Yun TJ, Kim TM, [Lee SH](#), Park CK, Kim JH, Sohn CH, Park SH, Kim IH. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. PLoS One. 2014 Nov 24;9(11):e113587. doi: 10.1371/journal.pone.0113587. eCollection 2014. PubMed PMID: 25419975; PubMed Central PMCID: PMC4242641.

312. Sim SH, Kim YJ, Kim SH, Keam B, Kim TM, [Lee SH](#), Kim DW, Heo DS, Lee JS. Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer. **J Cancer Res Clin Oncol**. 2015 Jun;141(6):1073-81. doi: 10.1007/s00432-014-1875-0. Epub 2014 Nov 20. PubMed PMID: 25410789.

313. Keam B, Ha H, Kim TM, Jeon YK, [Lee SH](#), Kim DW, Kim CW, Heo DS. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. **Leuk Lymphoma**. 2015 Jan 21:1-7. [Epub ahead of print] PubMed PMID: 25382617.

314. Yun TJ, Park CK, Kim TM, [Lee SH](#), Kim JH, Sohn CH, Park SH, Kim IH, Choi SH. Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy: Differentiation of True Progression from Pseudoprogression with Quantitative Dynamic Contrast-enhanced MR Imaging. **Radiology**. 2014 Oct 21:132632. [Epub ahead of print] PubMed PMID: 25333475.

315. Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). **Ann Hematol**. 2014 Oct 11. [Epub ahead of print] PubMed PMID: 25300500.

316. Wen H, Cho HR, Yun T, Kim H, Park CK, Lee SH, Choi SH, Park S. Metabolomic comparison between cells overexpressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. **J Neurochem**. 2014 Sep 23. doi: 10.1111/jnc.12950. [Epub ahead of print] PubMed PMID: 25251602.

317. Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. **J Neurooncol**. 2014 Sep 10. [Epub ahead of print] PubMed PMID: 25205290.

318. Lee JL, Park SH, Koh SJ, Lee SH, Kim YJ, Choi YJ, Lee J, Lim HY. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. **Cancer Chemother Pharmacol**. 2014 Nov;74(5):1005-13. doi: 10.1007/s00280-014-2579-5. Epub 2014 Sep 6. PubMed PMID: 25193433.

319. Kwon J, Chie EK, Kim K, Kim HJ, Wu HG, Kim IH, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Ha SW. Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. **J Korean Med Sci**. 2014 Aug;29(8):1094-101. doi: 10.3346/jkms.2014.29.8.1094. Epub 2014 Jul 30. PubMed PMID: 25120319; PubMed Central PMCID: PMC4129201.

320. Bae SH, Park MJ, Lee MM, Kim TM, Lee SH, Cho SY, Kim YH, Kim YJ, Park CK, Kim CY. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. **J Korean Med Sci**. 2014 Jul;29(7):980-4. doi: 10.3346/jkms.2014.29.7.980. Epub 2014 Jul 11. PubMed PMID: 25045231; PubMed Central PMCID: PMC4101787.

321. Kim BH, Kim IH, Park SH, Park CK, Jung HW, Kim TM, Lee SH, Heo DS. Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma. **Cancer Res Treat**. 2014 Jul;46(3):261-9. doi: 10.4143/crt.2014.46.3.261. Epub 2014 Jul 15. PubMed PMID: 25038761; PubMed Central PMCID: PMC4132445.

322. Lee HJ, Heo DS, Cho JY, Han SW, Chang HJ, Yi HG, Kim TE, [Lee SH](#), Oh DY, Im SA, Jang IJ, Bang YJ. A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. **Cancer Res Treat.** 2014 Jul;46(3):234-42. doi: 10.4143/crt.2014.46.3.234. Epub 2014 Jul 15. PubMed PMID: 25038758; PubMed Central PMCID: PMC4132447.

323. Keam B, Kim DW, Park JH, Lee JO, Kim TM, [Lee SH](#), Chung DH, Heo DS. Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. **Cancer Res Treat.** 2014 Oct;46(4):323-30. doi: 10.4143/crt.2013.120. Epub 2014 Jul 14. PubMed PMID: 25036571; PubMed Central PMCID: PMC4206063.

324. Sim SH, Keam B, Kim DW, Kim TM, [Lee SH](#), Chung DH, Heo DS. The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. **J Cancer Res Clin Oncol.** 2014 Jul 9. [Epub ahead of print] PubMed PMID: 25005787.

325. Kim BH, Kim HJ, Wu HG, Kang CH, Kim YT, [Lee SH](#), Kim DW. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage n2 non-small-cell lung cancer: a propensity score matching analysis. **Clin Lung Cancer.** 2014 Sep;15(5):356-64. doi: 10.1016/j.clcc.2014.05.005. Epub 2014 Jun 6. PubMed PMID: 24996882.

326. Shin DY, Kim DW, Keam B, Kim TM, [Lee SH](#), Kang CH, Kim YT, Heo DS. The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: A retrospective cohort study. **Lung Cancer.** 2014 Aug;85(2):320-5. doi: 10.1016/j.lungcan.2014.05.021. Epub 2014 Jun 4. PubMed PMID: 24954359.

327. [Park CK](#), [Lee SH](#), Kim JY, Kim JE, Kim TM, Lee ST, Choi SH, Park SH, Kim IH. Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. **Oncotarget.** 2014 May 30;5(10):3399-407. PubMed PMID: 24930669; PubMed Central PMCID: PMC4102818. [corresponding author]

328. An YJ, Cho HR, Kim TM, Keam B, Kim JW, Wen H, Park CK, [Lee SH](#), Im SA, Kim JE, Choi SH, Park S. An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients. **Int J Cancer.** 2015 Jan 1;136(1):162-71. doi: 10.1002/ijc.28949. Epub 2014 May 20. PubMed PMID: 24798643.

329. Kim YJ, Kim SJ, Lee JK, Choi WS, Park JH, Kim HJ, Sim SH, Lee KW, [Lee SH](#), Kim JH, Kim DW, Lee JS, Bang YJ, Heo DS. Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. **J Cancer Res Clin Oncol**. 2014 May 4. [Epub ahead of print] PubMed PMID: 24793643.

330. Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, [Lee SH](#), Heo DS. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. **JAMA**. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314. PubMed PMID: 24715074.

331. Lim YJ, Kim IH, Han TJ, Choi SH, Park SH, Park CK, Paek SH, [Lee SH](#), Kim TM. Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. **Int J Clin Oncol**. 2014 Apr 5. [Epub ahead of print] PubMed PMID: 24705988.

332. [Lee SH*](#), Bang YJ, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman Lowenthal S, Chung HC. Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. **Asia Pac J Clin Oncol**. 2014 Sep;10(3):237-45. doi: 10.1111/ajco.12163. Epub 2014 Feb 27. PubMed PMID: 24576311. [corresponding author]

333. Baek SH, Kim H, Lee J, Kim DK, Oh KH, Kim YS, Han JS, Kim TM, [Lee SH](#), Joo KW. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. **Korean J Intern Med**. 2014 Jan;29(1):40-8. doi: 10.3904/kjim.2014.29.1.40. Epub 2014 Jan 2. PubMed PMID: 24574832; PubMed Central PMCID: PMC3932394.

334. Jung JW, Kang HR, [Lee SH](#), Cho SH. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. **Oncology**. 2014;86(3):127-34. doi: 10.1159/000357711. Epub 2014 Jan 29. PubMed PMID: 24480856.

335. Lee YG, Kim I, Lee E, Bang SM, Kang CH, Kim YT, Kim HJ, Wu HG, Kim YW, Kim TM, Lee KW, Lee SH, Kim DW, Heo DS. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. **Thromb Haemost**. 2014 Jun;111(6):1112-20. doi: 10.1160/TH13-11-0956. Epub 2014 Jan 30. PubMed PMID: 24477503.

336. [Lee SH](#), Sim SH, Kim JY, Cha S, Song A. Application of cancer genomics to solve unmet clinical needs. **Genomics Inform**. 2013 Dec;11(4):174-9. doi:

[10.5808/GI.2013.11.4.174](#). Epub 2013 Dec 31. Review. PubMed PMID: 24465227; PubMed Central PMCID: PMC3897843. [corresponding author]

337. Kim JW, Koh Y, Kim DW, Ahn YO, Kim TM, Han SW, Oh DY, Lee SH, Im SA, Kim TY, Heo DS, Bang YJ. Clinical Implications of VEGF, TGF- β 1, and IL-1 β in Patients with Advanced Non-small Cell Lung Cancer. **Cancer Res Treat**. 2013 Dec;45(4):325-33. doi: 10.4143/crt.2013.45.4.325. Epub 2013 Dec 31. PubMed PMID: 24454005; PubMed Central PMCID: PMC3893330.

338. Ohn JH, Kim YG, Lee SH, Jung HS. Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib. **Endocrinol Metab (Seoul)**. 2013 Jun;28(2):149-52. doi: 10.3803/EnM.2013.28.2.149. Epub 2013 Jun 18. PubMed PMID: 24396670; PubMed Central PMCID: PMC3811707.

339. Wen H, Yun T, Xu WJ, Choi SH, Kim H, Park CK, Lee SH, Park SW, Lee SK, Park S. A highly facile and specific assay for cancer-causing isocitrate dehydrogenase mutant using ¹³C4-labeled α -ketoglutarate and heteronuclear NMR. **Anal Chem**. 2013 Dec 17;85(24):11987-92. doi: 10.1021/ac402947a. Epub 2013 Nov 22. PubMed PMID: 24266712.

340. Go SI, Keam B, Kim TM, Lee SH, Kim DW, Kim HJ, Wu HG, Chung DH, Heo DS. Clinical significance of downstaging in patients with limited-disease small-cell lung cancer. **Clin Lung Cancer**. 2014 Mar;15(2):e1-6. doi: 10.1016/j.clcc.2013.09.003. Epub 2013 Nov 14. PubMed PMID: 24356090.

341. Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS. How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution. **Cancer Res Treat**. 2013 Sep;45(3):178-85. doi: 10.4143/crt.2013.45.3.178. Epub 2013 Sep 30. PubMed PMID: 24155676; PubMed Central PMCID: PMC3804729.

342. Go H, Kim DW, Kim D, Keam B, Kim TM, Lee SH, Heo DS, Bang YJ, Chung DH. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. **J Thorac Oncol**. 2013 Nov;8(11):1445-50. doi: 10.1097/JTO.0b013e3182a4dd6e. PubMed PMID: 24128715.

343. Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. **Int J Clin Oncol**. 2013 Aug 6. [Epub ahead of print] PubMed PMID: 23912954.

344. Song YS, Choi SH, Park CK, Yi KS, Lee WJ, Yun TJ, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Jahng GH, Chang KH. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. **Korean J Radiol.** 2013 Jul-Aug;14(4):662-72. doi: 10.3348/kjr.2013.14.4.662. Epub 2013 Jul 17. PubMed PMID: 23901325; PubMed Central PMCID: PMC3725362.

345. Yoon HJ, Paeng JC, Kwak C, Park YH, Kim TM, Lee SH, Chung JK, Edmund Kim E, Lee DS. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. **Ann Nucl Med.** 2013 Oct;27(8):748-55. doi: 10.1007/s12149-013-0742-4. Epub 2013 Jul 2. PubMed PMID: 23818007.

346. Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. **J Thorac Oncol.** 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8. PubMed PMID: 23804027.

347. Park CK, Kim JH, Nam DH, Kim CY, Chung SB, Kim YH, Seol HJ, Kim TM, Choi SH, Lee SH, Heo DS, Kim IH, Kim DG, Jung HW. A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. **Neuro Oncol.** 2013 Aug;15(8):1096-101. doi: 10.1093/neuonc/not069. Epub 2013 Jun 25. PubMed PMID: 23800677; PubMed Central PMCID: PMC3714158.

348. Lee JK, Im SA, Lee D, Kim JY, Lim Y, Lee E, Moon HG, Kim TY, Han SW, Oh DY, Lee SH, Han W, Kim DW, Kim TY, Noh DY. Efficacy of exemestane in Korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors. **J Breast Cancer.** 2013 Mar;16(1):66-71. doi: 10.4048/jbc.2013.16.1.66. Epub 2013 Mar 31. PubMed PMID: 23593084; PubMed Central PMCID: PMC3625772.

349. Kim TM, Kim S, Ahn YO, Lee SH, Kim DW, Heo DS. Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. **Leuk Lymphoma.** 2014 Apr;55(4):940-3. doi: 10.3109/10428194.2013.813505. Epub 2013 Jul 29. PubMed PMID: 23772641.

350. Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, Jung SC, Lee AL, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. **Radiology.** 2013 Dec;269(3):831-40. doi: 10.1148/radiol.13122024. Epub 2013 Oct 28. PubMed PMID: 23771912.

351. Lee JH, Wu HG, Kim HJ, Park CI, [Lee SH](#), Kim DW, Heo DS. Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer. **Radiat Oncol J**. 2013 Mar;31(1):18-24. doi: 10.3857/roj.2013.31.1.18. Epub 2013 Mar 31. PubMed PMID: 23620865; PubMed Central PMCID: PMC3633227.

352. Hur S, Chung JW, Kim HC, Oh DY, [Lee SH](#), Bang YJ, Kim WH. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. *J Vasc Interv Radiol*. 2013 Jul;24(7):947-56; quiz 957. doi: 10.1016/j.jvir.2013.02.030. Epub 2013 Apr 19. PubMed PMID: 23602421.

353. Lee JK, Im SA, Lee D, Kim JY, Lim Y, Lee E, Moon HG, Kim TY, Han SW, Oh DY, [Lee SH](#), Han W, Kim DW, Kim TY, Noh DY. Efficacy of exemestane in Korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors. **J Breast Cancer**. 2013 Mar;16(1):66-71. doi: 10.4048/jbc.2013.16.1.66. Epub 2013 Mar 31. PubMed PMID: 23593084; PubMed Central PMCID: PMC3625772.

354. Lim Y, Keam B, Koh Y, Kim TM, [Lee SH](#), Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS, Kim KH. Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy. **Oral Surg Oral Med Oral Pathol Oral Radiol**. 2013 Jul;116(1):55-60. doi: 10.1016/j.oooo.2013.02.007. Epub 2013 Apr 6. PubMed PMID: 23570665.

355. Keam B, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N, Lee SH, Han W, Moon WK, Kim DW, Kim TY, Park IA, Noh DY. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. **Ann Surg Oncol**. 2013 Jul;20(7):2242-9. doi: 10.1245/s10434-012-2756-x. Epub 2013 Mar 26. PubMed PMID: 23529780.

356. Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, [Lee SH](#), Kim JI. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. **Ann Oncol**. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4. PubMed PMID: 23559152. [corresponding author]

357. Kim YH, Park CK, Kim TM, Choi SH, Kim YJ, Choi BS, Han JH, [Lee SH](#), Kim CY, Kim IA, Heo DS, Kim IH, Kim DG, Jung HW. Seizures during the management of high-grade gliomas: clinical relevance to disease progression. **J Neurooncol**. 2013 May;113(1):101-9. doi: 10.1007/s11060-013-1094-6. Epub 2013 Mar 4. PubMed PMID: 23459994.

358. Hwang EJ, Cha Y, Lee AL, Yun TJ, Kim TM, Park CK, Kim JH, Sohn CH, Park SH, Kim IH, Heo DS, [Lee SH](#), Choi SH. Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging. **J Neurooncol.** 2013 May;112(3):427-35. doi: 10.1007/s11060-013-1072-z. Epub 2013 Feb 17. PubMed PMID: 23417358. [corresponding author]

359. Park CK, [Lee SH](#), Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. **J Neurooncol.** 2013 Apr;112(2):277-83. doi: 10.1007/s11060-013-1060-3. Epub 2013 Feb 2. PubMed PMID: 23377829. [corresponding author]

360. Lee KH, Keam B, Im SA, Kim TY, Han SW, Oh DY, Kim JH, [Lee SH](#), Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data. **J Breast Cancer.** 2012 Dec;15(4):427-33. doi: 10.4048/jbc.2012.15.4.427. Epub 2012 Dec 31. PubMed PMID: 23346172; PubMed Central PMCID: PMC3542851.

361. Myung JK, Cho H, Park CK, Kim SK, [Lee SH](#), Park SH. Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. **Transl Oncol.** 2012 Dec;5(6):430-6. Epub 2012 Dec 1. PubMed PMID: 23323158; PubMed Central PMCID: PMC3542839.

362. Park JH, Kim TM, Keam B, Jeon YK, [Lee SH](#), Kim DW, Chung DH, Kim YT, Kim YW, Heo DS. Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. **Clin Lung Cancer.** 2013 Jan 9. doi:pji: S1525-7304(12)00259-8. 10.1016/j.clc.2012.10.007. [Epub ahead of print] PubMed PMID: 23313171.

363. Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, [Lee SH](#), Kim DW, Lee DS, Kim CW, Chung JK, Kim IH, Heo DS. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. **Cancer.** 2013 Mar 15;119(6):1195-202. doi: 10.1002/cncr.27855. Epub 2012 Dec 4. PubMed PMID: 23212736.

364. Koh Y, Lee HE, Oh DY, Kim JH, [Lee SH](#), Kim SH, Kim DW, Im SA, Kim TY, Heo DS, Kim WH, Bang YJ. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. **Jpn J Clin Oncol.** 2012 Nov;42(11):1020-7. doi: 10.1093/jjco/hys138. Epub 2012 Sep 5. PubMed PMID: 22952296.

365. Lee JK, Keam B, An AR, Kim TM, [Lee SH](#), Kim DW, Heo DS. Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. **Support Care Cancer.** 2013

Jan;21(1):183-90. doi: 10.1007/s00520-012-1509-5. Epub 2012 May 31. PubMed PMID: 22644263.

366. Lee JK, Kim TM, Koh Y, [Lee SH](#), Kim DW, Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW, Heo DS, Bang YJ. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. **Lung Cancer**. 2012 Aug;77(2):460-3. doi: 10.1016/j.lungcan.2012.04.012. Epub 2012 May 21. PubMed PMID: 22622260.

367. Park JH, [Lee SH](#), Keam B, Kim TM, Kim DW, Yang SC, Kim YW, Heo DS. EGFR mutations as a predictive marker of cytotoxic chemotherapy. **Lung Cancer**. 2012 Aug;77(2):433-7. doi: 10.1016/j.lungcan.2012.03.020. Epub 2012 Apr 21. PubMed PMID: 22521649.

368. Kim SJ, Kim DW, Kim TM, [Lee SH](#), Heo DS, Bang YJ. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. **J Clin Oncol**. 2012 Jun 1;30(16):e147-50. doi: 10.1200/JCO.2011.39.9766. Epub 2012 Apr 16. PubMed PMID: 22508824. (case study)

369. Park HS, Lee JK, Kim DW, Kulig K, Kim TM, [Lee SH](#), Jeon YK, Chung DH, Heo DS. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. **Lung Cancer**. 2012 Aug;77(2):288-92. doi: 10.1016/j.lungcan.2012.03.004. Epub 2012 Mar 31. PubMed PMID: 22465695.

370. Sim SH, Ahn YO, Yoon J, Kim TM, [Lee SH](#), Kim DW, Heo DS. Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. **Cancer Sci**. 2012 Feb;103(2):155-60. doi: 10.1111/j.1349-7006.2011.02158.x. Epub 2011 Dec 23. PubMed PMID: 22107611.

371. Lee JK, Park HS, Kim DW, Kulig K, Kim TM, [Lee SH](#), Jeon YK, Chung DH, Heo DS, Kim WH, Bang YJ. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. **Cancer**. 2012 Jul 15;118(14):3579-86. doi: 10.1002/cncr.26668. Epub 2011 Nov 15. PubMed PMID: 22086654.

372. Yoo RE, Choi SH, Cho HR, Kim TM, [Lee SH](#), Park CK, Park SH, Kim IH, Yun TJ, Kim JH, Sohn CH, Han MH, Chang KH. Tumor blood flow from arterial spin labeling perfusion MRI: A key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas. **J Magn Reson Imaging**. 2013 Feb 6. [Epub ahead of print] PubMed PMID: 23390061.

373. Lee KH, Keam B, Im SA, Kim TY, Han SW, Oh DY, Kim JH, [Lee SH](#), Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data. **J Breast Cancer**. 2012 Dec;15(4):427-33. PubMed PMID: 23346172; PubMed Central PMCID: PMC3542851.

374. Kim S, Kim TM, Kim DW, Go H, Keam B, [Lee SH](#), Ku JL, Chung DH, Heo DS. Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. **J Thorac Oncol**. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0. PubMed PMID: 23344087.

375. Lee JH, Wu HG, Kim HJ, Kim DW, [Lee SH](#), Kim TM, Kim YW, Heo DS. Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients. **Cancer Res Treat**. 2012 Dec;44(4):242-50. PubMed PMID: 23341788; PubMed Central PMCID: PMC3546271.

376. Koo TR, Wu HG, Hah JH, Sung MW, Kim KH, Keam B, Kim TM, [Lee SH](#), Kim DW, Heo DS, Park CI. Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer. **Cancer Res Treat**. 2012 Dec;44(4):227-34. PubMed PMID: 23341786; PubMed Central PMCID: PMC3546269.

377. Park JH, Kim TM, Keam B, Jeon YK, [Lee SH](#), Kim DW, Chung DH, Kim YT, Kim YW, Heo DS. Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. **Clin Lung Cancer**. 2013 Jan 9. [Epub ahead of print] PubMed PMID: 23313171.

378. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, [Lee SH](#), Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. **J Mol Diagn**. 2013 Jan;15(1):51-61. PubMed PMID: 23246132.

379. Koh Y, Lim HY, Ahn JH, [Lee JL](#), Rha SY, Kim YJ, Kim TM, [Lee SH](#). Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. **Ann Oncol**. 2013 Apr;24(4):1026-31. Epub 2012 Nov 23. PubMed PMID: 23180114. [corresponding author]

380. Park CK, Kim JE, Kim JY, Song SW, Kim JW, Choi SH, Kim TM, [Lee SH](#), Kim IH, Park SH. The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. **Transl Oncol**. 2012 Oct;5(5):393-7. PubMed PMID: 23066447; PubMed Central PMCID: PMC3468928.

381. Sunwoo L, Choi SH, Park CK, Kim JW, Yi KS, Lee WJ, Yoon TJ, Song SW, Kim JE, Kim JY, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Chang KH. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. **J Magn Reson Imaging**. 2012 Sep 28. [Epub ahead of print] PubMed PMID: 23023975.

382. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT. The transcriptional landscape and mutational profile of lung adenocarcinoma. **Genome Res**. 2012 Nov;22(11):2109-19. pub 2012 Sep 13. PubMed PMID: 22975805; PubMed Central PMCID: PMC3483540.

383. Koh Y, Lee HE, Oh DY, Kim JH, Lee SH, Kim SH, Kim DW, Im SA, Kim TY, Heo DS, Kim WH, Bang YJ. The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use. **Jpn J Clin Oncol**. 2012 Sep 5. [Epub ahead of print] PubMed PMID: 22952296.

384. Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. **Proc Natl Acad Sci U S A**. 2012 Sep 4;109(36):14476-81. Epub 2012 Aug 20. PubMed PMID: 22908275; PubMed Central PMCID: PMC3437859.

385. Lee WJ, Choi SH, Park CK, Yi KS, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH. Diffusion-weighted MR Imaging for the Differentiation of True Progression from Pseudoprogression following Concomitant Radiotherapy with Temozolomide in Patients with Newly Diagnosed High-grade Gliomas. **Acad Radiol**. 2012 Aug 9. [Epub ahead of print] PubMed PMID: 22884399.

386. Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, Naito S, Cincotta M, Tokushige K, Akaza H. Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma. **Jpn J Clin Oncol**. 2012 Sep;42(9):836-44. Epub 2012 Jul 26. PubMed PMID: 22844126.

387. Park Dewitt J, Kim YH, Han JH, Lee SH, Kim IH, Choe G, Kim CY. Primary intracranial germ cell tumor originating from septum pellucidum that mimics central neurocytoma. **J**

Clin Oncol. 2012 Sep 20;30(27):e274-7. Epub 2012 Jul 23. PubMed PMID: 22826280 [case report].

388.Han TJ, Kim HJ, Wu HG, Heo DS, Kim YW, [Lee SH](#). Comparison of Treatment Outcomes Between Involved-field and Elective Nodal Irradiation in Limited-stage Small Cell Lung Cancer. **Jpn J Clin Oncol.** 2012 Jul 17. [Epub ahead of print] PubMed PMID: 22811409.

389.Kim SK, Kim JW, Kim YH, Kim TM, [Lee SH](#), Park CK. The role of chemotherapy in anaplastic astrocytoma patients. **J Korean Neurosurg Soc.** 2012 Apr;51(4):199-202. Epub 2012 Apr 30. PubMed PMID: 22737298; PubMed Central PMCID: PMC3377875.

390.Bae HM, [Lee SH](#), Kim TM, Kim DW, Yang SC, Wu HG, Kim YW, Heo DS. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. **Lung Cancer.** 2012 Sep;77(3):572-7. PubMed PMID: 22672969.

391.Lee JK, Kim TM, Koh Y, [Lee SH](#), Kim DW, Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW, Heo DS, Bang YJ. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. **Lung Cancer.** 2012 Aug;77(2):460-3. Epub 2012 May 21. PubMed PMID: 22622260.

392.Park JH, [Lee SH](#), Keam B, Kim TM, Kim DW, Yang SC, Kim YW, Heo DS. EGFR mutations as a predictive marker of cytotoxic chemotherapy. **Lung Cancer.** 2012 Aug;77(2):433-7. PubMed PMID: 22521649.

393.Kim SJ, Kim DW, Kim TM, Lee SH, Heo DS, Bang YJ. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. **J Clin Oncol.** 2012 Jun 1;30(16):e147-50. Epub 2012 Apr 16. PubMed PMID: 22508824 [case report].

394.Park HS, Lee JK, Kim DW, Kulig K, Kim TM, [Lee SH](#), Jeon YK, Chung DH, Heo DS. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. **Lung Cancer.** 2012 Mar 30. [Epub ahead of print] PubMed PMID: 22465695.

395.Sim SH, Ahn YO, Yoon J, Kim TM, Lee SH, Kim DW, Heo DS. Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. **Cancer Sci.** 2012 Feb;103(2):155-60. doi: 10.1111/j.1349-7006.2011.02158.x. Epub 2011 Dec 23. PubMed PMID: 22107611.

396. Son KY, Lee CH, Park SM, Lee CH, Oh SI, Oh B, Tak SH, Cho B, Lee K, [Lee SH](#). The Factors Associated with the Quality of Life of the Spouse Caregivers of Patients with Cancer: A Cross-Sectional Study. **J Palliat Med**. 2012 Jan 27. [Epub ahead of print] PubMed PMID: 22283431.

397. [Lee SH](#). Role of chemotherapy on brain metastasis. **Prog Neurol Surg**. 2012;25:110-4. Epub 2012 Jan 6. Review. PubMed PMID: 22236672.

398. Sim SH, Ahn YO, Yoon J, Kim TM, [Lee SH](#), Kim DW, Heo DS. Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. **Cancer Sci**. 2012 Feb;103(2):155-60. doi: 10.1111/j.1349-7006.2011.02158.x. Epub 2011 Dec 23. PubMed PMID: 22107611.

399. Lee JK, Park HS, Kim DW, Kulig K, Kim TM, [Lee SH](#), Jeon YK, Chung DH, Heo DS, Kim WH, Bang YJ. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. **Cancer**. 2011 Nov 15. doi: 10.1002/cncr.26668. [Epub ahead of print] PubMed PMID: 22086654.

400. Choi J, Suh B, Ahn YO, Kim TM, Lee JO, Lee SH, Heo DS. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. **Tumour Biol**. 2012 Feb;33(1):121-9. Epub 2011 Nov 13. PubMed PMID: 22081309.

401. Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Noh DY, Heo DS, Park IA, Bang YJ, Ha SW. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. **J Neurooncol**. 2012 Jan;106(2):303-13. Epub 2011 Sep 22. PubMed PMID: 21938531.

402. Barrios CH, Hernandez-Barajas D, Brown MP, [Lee SH](#), Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. **Cancer**. 2012 Mar 1;118(5):1252-9. doi: 10.1002/cncr.26440. Epub 2011 Sep 6. PubMed PMID: 21898376.

403. Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, [Lee SH](#), Bang YJ, Rha SY. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable

efficacy with different toxicity profiles. **Oncology**. 2011;80(5-6):395-405. Epub 2011 Aug 5. PubMed PMID: 21829041.

404. Koh Y, Lee HE, Im SA, Kim SH, Kim TM, Han SW, Oh DY, Kim JH, Lee SH, Kim DW, Kim TY, Kim WH, Heo DS, Bang YJ. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. **Diagn Mol Pathol**. 2011 Sep;20(3):143-7. doi: 10.1097/PDM.0b013e3182107ea0. PubMed PMID: 21817899.

405. Kim KH, Kim TM, Go H, Kim WY, Jeon YK, Lee SH, Kim DW, Khwarg SI, Kim CW, Heo DS. Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. **Cancer Sci**. 2011 Nov;102(11):1972-6. doi: 10.1111/j.1349-7006.2011.02051.x. Epub 2011 Sep 6. PubMed PMID: 21812857.

406. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirota N, Bodrogi I; REACT Study Group. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. **Eur J Cancer**. 2012 Feb;48(3):324-32. Epub 2011 Jul 29. PubMed PMID: 21803569.

407. Keam B, Im SA, Park S, Nam BH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. **J Cancer Res Clin Oncol**. 2011 Sep;137(9):1301-8. Epub 2011 Jun 30. PubMed PMID: 21717200.

408. Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal Tract, and Lung). **Am J Clin Oncol**. 2011 Jun 8. [Epub ahead of print] PubMed PMID: 21659833.

409. Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS, Bang YJ. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. **J Thorac Oncol**. 2011 Sep;6(9):1474-80. PubMed PMID: 21642865.

410. Kim SH, Shin SJ, Kim SY, Lee SH, Park YS, Park SH, Lee KH, Kim TW, Hong YS, Ahn JB. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal

carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. **Cancer Chemother Pharmacol**. 2012 Jan;69(1):91-7. Epub 2011 May 24. PubMed PMID: 21607556.

411. Shin DY, Jeon YK, Hong YS, Kim TM, [Lee SH](#), Kim DW, Kim I, Yoon SS, Heo DS, Park S, Kim BK. Clinical dissection of multicentric Castleman disease. **Leuk Lymphoma**. 2011 Aug;52(8):1517-22. Epub 2011 May 17. PubMed PMID: 21585280.

412. Koh Y, Kim DW, Kim TM, [Lee SH](#), Jeon YK, Chung DH, Kim YW, Heo DS, Kim WH, Bang YJ. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. **J Thorac Oncol**. 2011 May;6(5):905-12. PubMed PMID: 21358343.

413. Koh Y, Jang B, Jeon YK, Kim TM, [Lee SH](#), Kim DW, Chung DH, Kim YT, Kim YW, Heo DS. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. **Jpn J Clin Oncol**. 2011 Apr;41(4):548-54. Epub 2011 Jan 19. PubMed PMID: 21247966.

414. Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, [Lee SH](#), Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. **Support Care Cancer**. 2011 Mar 11. [Epub ahead of print]

415. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. **Breast Cancer Res**. 2011 Mar 2;13(2):R22. [Epub ahead of print]

416. Kim JS, Kim MA, Oh DY, Lee SH, Kim DW, Im SA, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Kim TY, Kim TM, Kim NK, Choe KJ. Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. **Jpn J Clin Oncol**. 2011 Feb;41(2):245-52.

417. Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, Park SH, Kim TM, Lee SH, Choi SH, Kim SK, Kim DG, Jung HW. Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. **Neuro Oncol**. 2011 Feb;13(2):195-202.

418. Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee SH, Carteni G, Nieto A, Yuan J, Szczalik C. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. **Cancer**. 2011 Feb 1;117(3):501-9.
419. Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. **Lung Cancer**. 2011 Jan;71(1):65-9.
420. Kim IH, Park CK, Heo DS, Kim CY, Rhee CH, Nam DH, Lee SH, Han JH, Lee SH, Kim TM, Kim DW, Kim JE, Paek SH, Kim DG, Kim IA, Kim YJ, Kim JH, Park BJ, Jung HW. Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. **J Neurooncol**. 2010 Nov 4. [Epub ahead of print]
421. Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, Jung HW, Chang KH. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. **Clin Neurol Neurosurg**. 2010 Nov;112(9):758-65.
422. Kim SJ, Kim JW, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Seog Heo D, Bang YJ. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. **BMC Cancer**. 2010 Aug 23;10:448.
423. Son KY, Park SM, Lee CH, Choi GJ, Lee D, Jo S, Lee SH, Cho B. Behavioral risk factors and use of preventive screening services among spousal caregivers of cancer patients. **Support Care Cancer**. 2011 Jul;19(7):919-27. Epub 2010 May 6. PubMed PMID: 20445996.
424. Jang NY, Wu HG, Park CI, Heo DS, Kim DW, Lee SH, Rhee CS. Definitive Radiotherapy With or Without Chemotherapy for T3-4N0 Squamous Cell Carcinoma of the Maxillary Sinus and Nasal Cavity. **Jpn J Clin Oncol**. 2010 Jun;40(6):542-8.
425. Sun JM, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Lee JS, Kim YW, Heo DS, Bang YJ. The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. **Lung Cancer**. 2010 Jun;68(3):427-32.

426. Son KY, Park SM, Lee CH, Choi GJ, Lee D, Jo S, Lee SH, Cho B. Behavioral risk factors and use of preventive screening services among spousal caregivers of cancer patients. **Support Care Cancer**. 2010 May 6. [Epub ahead of print]
427. Kim TM, Kim KH, Lee MJ, Jeon YK, Lee SH, Kim DW, Kim CW, Kim IH, Khwarg SI, Heo DS. First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. **Cancer Sci**. 2010 May;101(5):1199-203.
428. Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. **J Thorac Oncol**. 2010 Mar;5(3):320-5.
429. Kim WY, Jeon YK, Kim TM, Kim JE, Kim YA, Lee SH, Kim DW, Heo DS, Kim CW. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. **Ann Oncol**. 2009 Oct;20(10):1688-96.
430. Kim K, Wu HG, Kim HJ, Sung MW, Kim KH, Lee SH, Heo DS, Park CI. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. **Head Neck**. 2009 Sep;31(9):1121-8.
431. Park CK, Lee SH, Han JH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW. Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. **BMC Cancer**. 2009;9:450.
432. Sim SH, Kim YJ, Oh DY, Lee SH, Kim DW, Kang WJ, Im SA, Kim TY, Kim WH, Heo DS, Bang YJ. The role of PET/CT in detection of gastric cancer recurrence. **BMC Cancer**. 2009;9:73.
433. Sim SH, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim TY, Lee JS, Kim YW, Heo DS, Bang YJ. Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. **Lung Cancer**. 2009 Aug;65(2):204-7.
434. Park CK, Park SH, Lee SH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. **Neuropathology**. 2009 Aug;29(4):443-9.

435. Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, [Lee SH](#), Kim DW, Wu HG, Rhee CS, Sung MW, Kim CW, Kim KH, Heo DS. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. **Ann Oncol.** 2009 Aug;20(8):1414-9.

436. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, [Lee SH](#), Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. **Lancet Oncol.** 2009 Aug;10(8):757-63.

437. Kim HJ, Kim YJ, Seo MD, Yi HG, Lee SH, Lee SM, Kim DW, Yang SC, Lee CT, Lee JS, Kim YW, Heo DS. Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. **Lung Cancer.** 2009 Aug;65(2):242-6.

438. Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, [Lee SH](#), Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. **Lung Cancer.** 2009 Jul;65(1):80-4.

439. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, [Lee SH](#), Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. **Breast Cancer Res Treat.** 2009 Jul;116(1):153-60.

440. Han JH, Park CK, [Lee SH](#), Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW. Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis. **Chemotherapy.** 2009 May;55(3):145-54.

441. Kim JS, Kim MA, Kim TM, [Lee SH](#), Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ, Kim NK. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. **Br J Cancer.** 2009 Mar 10;100(5):732-8.

442. Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, [Lee SH](#), Jun HJ, Ahn JS, Kang WK, Park K, Im YH. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. **Int J Cancer.** 2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090. PubMed PMID: 19065658.

443. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Kim YJ, [Lee SH](#), Kim DW, Yang SC, Kim YW, Heo DS. Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. **Lung Cancer**. 2008 Dec;62(3):381-4.

444. Lee KH, Min HS, Han SW, Oh DY, [Lee SH](#), Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. **Lung Cancer**. 2008 Jun;60(3):401-7.

445. Song EK, Kim SY, Kim TM, Lee KW, Yun T, Na, Il, Shin H, [Lee SH](#), Kim DW, Khwarg SI, Heo DS. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. **Ann Oncol**. 2008 Feb;19(2):242-6.

446. Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, [Lee SH](#), Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. **Ann Oncol**. 2008 Jan;19(1):99-103.

447. Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. **BMC Cancer**. 2008;8:374.

448. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, [Lee SH](#), Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. **BMC cancer**. 2008;8:148.

449. [Lee S-H*](#). Chemoradiation for advanced laryngeal cancer. **Korean J Head Neck Oncol**. 2008;24(2):135-8. (review, in Korean)

450. Kim HJ, Kim JS, Seo MD, Oh SY, Oh DY, Kim JH, [Lee SH](#), Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. **Cancer Res Treat**. 2008 Jun;40(2):81-6. doi: 10.4143/crt.2008.40.2.81. Epub 2008 Jun 30. PubMed PMID: 19688053; PubMed Central PMCID: PMC2697482.

451. Keam B, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker. **Mol Med Rep**. 2008 May-Jun;1(3):415-22. PubMed PMID: 21479426.

452. Kim WS, Park YH, Lee SH, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im do H, Kang JH, Lee J, Ko YH, Ahn YC, Lim do H, Park K, Bang SM. Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. **Med Oncol.** 2008;25(4):447-50. doi: 10.1007/s12032-008-9065-z. Epub 2008 Apr 23. PubMed PMID: 18431552.

453. Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, Kim TY, Bang YJ, Heo DS. Aggressiveness of cancer-care near the end-of-life in Korea. **Jpn J Clin Oncol.** 2008 Apr 14; [Epub ahead of print]

454. Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, Lee SH, Im SA, Chung DH, Kim YT, Kim TY, Bang YJ, Sung SW, Kim JH, Heo DS. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected nonsmall cell lung cancer. **Br J Cancer.** 2008 Mar 25;98(6):1118-24.

455. Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. **Lung Cancer.** 2008 Jan 11; [Epub ahead of print]

456. Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW, Heo DS. Palliative chemotherapy for pulmonary pleomorphic carcinoma. **Lung Cancer.** 2007 Oct;58(1):112-5.

457. Oh DY, Kim JH, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. **Support Care Cancer.** 2007 Jun;15(6):631-6. 2006 Nov 11.

458. Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. **Pharmacogenet Genomics.** 2007 May;17(5):313-9.

459. Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. **BMC Cancer.** 2007 Apr 12;7:63.

460. Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. **Lung Cancer.** 2006 Nov;54(2):201-

7. Epub 2006 Sep 7.

461. Lee KH, [Lee SH](#), Kim DW, Kang WJ, Chung JK, Im SA, Kim TY, Kim YW, Bang YJ, Heo DS. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. **Clin Cancer Res.** 2006 Jul 15;12(14 Pt 1):4232-6.

462. Park YH*, [Lee SH*](#), Kim WS, Bang SM, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im do H, Kang JH, Lee J, Ko YH, Ahn YC, Lim do H, Park K. CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation. **Leuk Lymphoma.** 2006 Jul;47(7):1253-9. [*: equally contributed]

463. Lim do H, Lee J, Lee HG, Park BB, Peck KR, Oh WS, Ji SH, [Lee SH](#), Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Park K. Pulmonary complications after hematopoietic stem cell transplantation. **J Korean Med Sci** 2006 Jun;21(3):406-11.

464. [Lee SH](#), Ahn YC, Kim WS, Ko YH, Kim K, Park K. The effect of pre-irradiation dose intense CHOP on anthracycline resistance in localized nasal NK/T-cell lymphoma. **Haematologica.** 2006 Mar;91(3):427-8.

465. Park SH, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. **Cancer Chemother Pharmacol.** 2006 Jan;57(1):91-6.

466. Park BB, Kim WS, Lee J, Park KW, Kang JH, [Lee SH](#), Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K. IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. **Leuk Lymphoma.** 2005 Dec;46(12):1743-8.

467. Kim S, Lim do H, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, [Lee SH](#), Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. **Int J Radiat Oncol Biol Phys.** 2005 Dec 1;63(5):1279-85.

468. Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, [Lee SH](#), Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Ko YH, Ahn YC, Park K. Extranodal

nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. **Eur J Cancer**. 2005 Jul;41(10):1402-1408.

469. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, [Lee SH](#), Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. **Cancer Chemother Pharmacol**. 2005 Jul;56(1):10-14.

470. Kim ST, Kang WK, Kang JH, Park KW, Lee J, [Lee SH](#), Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. **Br J Cancer**. 2005 May 23;92(10):1850-1854.

471. Kim JH, Jung CW, Cho YH, Lee J, [Lee SH](#), Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. **Oncol Rep**. 2005 May;13(5):859-864.

472. Ji SH, Park YS, Lee J, Lim do H, Park BB, Park KW, Kang JH, [Lee SH](#), Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K. Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer. **Jpn J Clin Oncol**. 2005 Apr;35(4):214-217.

473. Lee J, Lee MH, Park KW, Kang JH, Im do H, Kim K, [Lee SH](#), Kim WS, Park J, Jung CW, Park K. Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission. **Int J Hematol**. 2005 Apr;81(3):258-263.

474. Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, [Lee SH](#), Kim K, Jung CW, Ahn YC, Ko YH, Park K. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. **Br J Cancer**. 2005 Apr 11;92(7):1226-1230.

475. Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, [Lee SH](#), Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S. Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. **J Cell Biochem**. 2005 Mar 1;94(4):695-707.

476. [Lee SH](#), Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. **Biol Blood**

Marrow Transplant. 2005 Feb;11(2):122-128.

477. Park S, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, [Lee SH](#), Kim WS, Jung CW, Park K, Riordan HD, Lee JH. Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. **Cell Signal.** 2005;17(1):111-119.

478. Kim HY, Lee MH, Kim JH, Lee S-H, Park J, Kim K, Park QE, Kim WS, Jung CW, Park K. Significance of multidrug resistance (MDR) activity in remission induction & survival of acute myeloid leukemia. **Korean J Hematol.** 2004; 39(4):209-216. (in Korean)

479. Ji SH, Park JO, Lee J, Oh MJ, Lim DH, Park BB, Park KW, [Lee S-H](#), Kim K, Kim WS, Jung CW, Park YS, Im Y-H, Kang WK, Lee MH, Park K. Three cases of synchronous solid tumor and multiple myeloma. **Cancer Res Treat.** 2004;36(5):338-340. (case report)

480. Park S, Han SS, Park CH, Hahm ER, Lee SJ, Park HK, [Lee SH](#), Kim WS, Jung CW, Park K, Riordan HD, Kimler BF, Kim K, Lee JH. l-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. **Int J Biochem Cell Biol.** 2004;36(11):2180-2195.

481. Kim JH, [Lee SH](#), Park J, Kim HY, Lee SI, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K, Han JH, Ko YH. Primary pulmonary non-Hodgkin's lymphoma. **Jpn J Clin Oncol.** 2004;34(9):510-514.

482. Park SH, Kang WK, Lee HR, Park J, Lee KE, [Lee SH](#), Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K. Docetaxel plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil based Regimen. **Am J Clin Oncol.** 2004 Oct;27(5):477-480.

483. [Lee S-H](#), Lee J, Park J, Park SH, Lee K-E, Lee SI, Nam E, Park JO, Kim K, Jung CW, Park YS, Yoon SS, Kang WK, Lee MH, Park K, Im Y-H. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. **Med Oncol.** 2004;21(3):223-232.

484. Lim DH, Im Y-H, Ji SH, Park BB, Oh MJ, Lee J, Park KW, [Lee S-H](#), Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Lee MH, Kim K, Shim YM, Park K. Esophageal squamous cell carcinoma recurring as a solitary renal mass. **Cancer Res Treat.** 2004;36(4):271-274. (case report)

485. [Lee SH](#), Kang WK, Park J, Kim HY, Kim JH, Lee SI, Park JO, Kim K, Jung CW, Park YS, Im YH, Lee MH, Park K. Combination chemotherapy with epirubicin, docetaxel and

cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. **Br J Cancer.** 2004;91(1):18-22.

486. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, Kim JH, Park SH, Lee KE, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. **Clin Cancer Res** 2004;10(13):4383-4388.

487. Kim JH*, Lee SH*, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Extrapulmonary Small-Cell Carcinoma: A single-institution experience. **Jpn J Clin Oncol.** 2004;34(5):250-254. [*: equally contributed]

488. Lee J, Lee MH, Kim WS, Kim K, Park SH, Lee SH, Lee KE, Park J, Park JO, Jung CW, Im YH, Kang WK, Park K. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. **Int J Hematol.** 2004;79(2):185-188.

489. Park SH, Lee MH, Lee SH, Lee KE, Park J, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K, Kim SW, Lee KH, Lee JH. The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation. **J Korean Med Sci.** 2004;19(1):79-82.

490. Lee SH, Ahn YC, Kim HJ, Lim DH, Lee SI, Nam EM, Park SH, Park J, Lee K-E, Park JO, Kim K, Kim WS, Jung CW, Im Y-H, Kang WK, Lee MH, Park K. Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer. **Jpn J Clin Oncol.** 2003;33(12):620-625.

491. Lee S-H, Lee JH, Im Y-H, Kang Y-K, Kim TY, Cho EK, Kim WS, Kim TW, Bang SM, Heo DS, Bang Y-J, Kim NK. A multicenter, phase III clinical trial of Leucogreen® (G-CSF) for chemotherapy-induced neutropenia in solid tumors. **Kor J Clin Pharmacol Ther.** 2003;11(1):38-47. (in Korean)

492. Park J, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim do H, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. **Lung Cancer.** 2003;42(2):227-235.

493. Park J, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia. **Bone Marrow Transplant.** 2003;32(9):889-895.

494. [Lee S-H](#), Park K, Suh C, Kim H-K, Kim J-S, Im Y-H, Kim S-W, Heo D-S, Bang Y-J, Kim NK. A Multi-Center, Phase II Clinical Trial of Genexol® (Paclitaxel) and Cisplatin in Patients with Non-Small-Cell Lung Cancer. **Cancer Res Treat.** 2003;35(1):30-34.

495. Kim JH, Kim DY, [Lee S-H](#), Park SR, Lee SY, Choi IS, Kim TY, Heo DS, Bang YJ, Kim NK. Combination chemotherapy of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high dose leucovorin every two weeks in recurrent or metastatic colorectal cancer. **Korean J Med.** 2003;64(4):452-458.

496. Park SR, Kim JH, Kim DY, [Lee SH](#), Lee SY, Choi IS, Yoon SS, Park S, Kim BG, Kim NK. Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors. **Korean J Intern Med.** 2003;18(1):21-28.

497. Choi IS, Kim BS, Park SR, Lee SY, Kim do Y, Kim JH, [Lee SH](#), Kim TY, Heo DS, Bang YJ, Kim NK. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. **Lung Cancer.** 2003;39(1):99-101.

498. Kim DY, Kim JH, [Lee SH](#), Kim TY, Heo DS, Bang YJ, Kim NK. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. **Ann Oncol.** 2003;14(3):383-387.

499. Choi IS, [Lee SH](#), Kim TY, Bang JS, Paek SH, Kim S, Kim IH, Heo DS, Bang YJ, Kim DG, Jung HW, Kim NK. Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. **J Neurooncol.** 2002;60(2):171-176.

500. Kim TY, Yang SH, [Lee SH](#), Park YS, Im YH, Kang WK, Ha SH, Park CI, Heo DS, Bang YJ, Kim NK. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. **Am J Clin Oncol.** 2002;25(3):238-243.

501. Kim BS, Oh DY, Joh YH, Kim DY, Kim JH, [Lee SH](#), Lee DH, Kim TY, Heo DS, Bang YJ, Kim NK. Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. **Cancer Res Treat.** 2001; 33(6):469-473.

502. Joh YH, Kim TY, Na II, Oh DY, Kim BS, Kim JH, Kim DY, [Lee SH](#), Yoo CG, Lee CT, Kim YH, Heo DS, Bang YJ, Han SK, Shim YS, Kim NK. Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer. **Cancer Res Treat.**

2001;33(5):373-376.

503. Oh DY, Kim MR, Choi IS, Jo YH, Kim BS, Kim DY, Kim JH, [Lee SH](#), Kim TY, Heo DS, Bang YJ, Kim NK. Discrepancies of the Values on the Withholding Futile Interventions between Physician and Family Members of Terminal Cancer Patients. **Cancer Res Treat.** 2001;33(4):350-353.

504. Bang SM, [Lee SH](#), Cho EK, Lee JA, Park YS, Shin DB, Lee JH, Bang YJ, Park SY, Kim BK, Kim NK. High Dose Chemotherapy with Ifosfamide, Carboplatin, and Etoposide Followed by Autologous Stem Cell Transplantation in Breast Cancer. **J Kor Cancer Assoc.** 2000;32(6):1059-1066. (in Korean)

505. [Lee SH](#), Cha HJ, Kim JH, Na II, Lee JH, Kim HK, Lee KS, Lee WS, Kim CJ, Heo DS, Bang YJ, Kim NK. Prognostic Factors of Gastrointestinal Leiomyosarcoma in Korea. **J Kor Cancer Assoc** 2000;32(6):1022-1030. (in Korean)

506. Kim HK, Bang SM, Byun JH, Ryu MH, Lee WS, Lee KS, Jeong JY, Kim JH, [Lee SH](#), Na II, Heo DS, Bang YJ, Kim NK. Prognostic factors of breast cancer in Koreans. **Kor J Med.** 2000;58(4):446-452.

507. [Lee SH](#), Kim DW, Jung KH, Bang SM, Byun JH, Chang HM, Heo DS, Bang YJ, Kim NK. Antiemetic Effect of Granisetron plus Dexamethasone for the Patients Refractory to Metoclopramide, Dexamethasone and Lorazepam (MDL). **J Kor Cancer Assoc.** 1999;31(5):1027-1034. (in Korean)

508. Kim KA, [Lee SH](#), Jang WJ, Oh MD, Kim IS, Choi KW. Two Cases of Tsutsugamushi Disease in the Spring. **Kor J Inf Dis.** 1999;31(1):46-49. (in Korean)

509. Kim IH, Park SY, [Lee SH](#), Kim DW, Kim BK, Kim NK, Kim SJ. Etiology and Clinical Aspects of Thromboembolism in Korea: Retrospective Analysis of Hereditary Thrombophilia in a Single Institution. **Kor J Thrombo Hemosta.** 1998; 5(2):115-122. (in Korean)

510. Ryu MH, Park YI, Kim HK, Lee DH, Jeong JY, Kim DW, Na II, Kim JH, [Lee SH](#), Heo DS, Bang YJ, Park SY, Kim BK, Kim NK. Prognostic Factor Analysis of Aggressive Non-Hodgkin's Lymphoma Based on International Prognostic Index Model. **J Kor Cancer Assoc.** 1998;30(6):1269-1278. (in Korean)